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ABSTRACT 
 
 
 
PEX5 interacts with de novo synthesized cargo-proteins in the cytosol, 
transports them to the peroxisomal membrane, and after release of the cargo into the 
matrix of the organelle is recycled back to the cytosol. The mechanism behind the 
interaction of PEX5 with cargoes remains poorly understood. Considering that matrix 
proteins are synthesized in the cytosol in the presence of PEX5, we asked whether or 
not PEX5 binds the monomeric forms of these proteins. We provide data on the 
interaction of PEX5 with catalase, a homotetrameric enzyme in its native state. PEX5 
interacts with monomeric catalase inhibiting its tetramerization, a feature that requires 
both the N- and C-terminal halves of PEX5. Interestingly, the PEX5-catalase interaction 
is disrupted by the N-terminal domain of PEX14, a component of the 
docking/translocation machinery. One or two of the seven PEX14-binding diaromatic 
motifs present in the N-terminal half of PEX5 are probably involved in this 
phenomenon. These observations were extended to two other major matrix proteins, 
acyl-CoA oxidase 1 and urate oxidase, showing that the interaction with PEX5 also 
inhibits their oligomerization. Furthermore, we found that the monomeric version of 
these proteins is more efficiently imported into the organelle matrix. Taken together, 
these results strongly suggest that PEX5 sequesters the newly synthesized 
peroxisomal proteins en route to the organelle, resembling a chaperone. We propose 
that this binding mode prevents premature oligomerization/non-specific interactions of 
cargo proteins, leading to a more efficient peroxisomal import.  
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RESUMO 
 
 
 
As proteínas da matriz peroxissomal são sintetizadas no citosol, onde 
posteriormente interactuam com o receptor PEX5. A PEX5 transporta estas proteínas 
para a membrana do organelo e, após libertação das mesmas para a matriz, é 
reciclada de volta ao citosol. O mecanismo de interacção do receptor PEX5 com as 
proteínas da matriz peroxissomal permanece por esclarecer. Tendo em consideração 
que as proteínas matriciais são sintetizadas no citosol na presença da PEX5, é lícito 
questionar se o receptor interactua ou não com a forma monomérica destas mesmas 
proteínas. Neste estudo fornecemos dados sobre a interacção da PEX5 com a 
catalase, uma enzima homotetramérica no seu estado nativo. A PEX5 interage com a 
catalase monomérica, inibindo a sua tetramerização, uma característica que requer 
ambos os domínios N- e C-terminais da PEX5. Na presença do domínio N-terminal da 
PEX14, um componente da maquinaria peroxissomal de docking/translocação, a PEX5 
dissocia-se da catalase. Dos sete domínios de interacção com a PEX14 presentes no 
N-terminal da PEX5, apenas um ou dois parecem estar envolvidos neste evento. Estes 
resultados foram confirmados com duas outras proteínas abundantes da matriz 
peroxisomal, a acil-CoA oxidase 1 e a urato oxidase, mostrando que a PEX5 também 
inibe a sua oligomerização. Os nossos resultados mostram que a versão monomérica 
destas proteínas é mais eficientemente importada para a matriz do organelo. Em 
conjunto, estes resultados sugerem que a PEX5 sequestra as proteínas da matriz 
peroxissomal após a sua síntese, apresentando características de uma chaperone. 
Propomos que esta ligação previne a oligomerização e interacções não específicas 
prematuras das proteínas matriciais, levando a um importe peroxissomal mais 
eficiente. 
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1. Peroxisome Structure and Function 
 
Peroxisomes are multifunctional organelles of eukaryotic cells. These structures 
were first described by Rhodin as microbodies [1], but in 1966 de Duve and Baudhuin 
discovered that they contained H2O2-producing oxidases and catalase, naming them 
peroxisomes [2]. Peroxisomes are ubiquitous and essential organelles delimited by a 
single membrane and, unlike mitochondria and chloroplasts, do not contain 
endogenous DNA [3-5], (Figure 1). This organelle may appear as elongated, tubular 
and reticular structures [3, 6-8]. One important feature of peroxisomes is their 
metabolic plasticity. Indeed, their number, morphology and function can vary widely 
depending on the organism, cell- or tissue-type and environmental conditions [3, 4, 9, 
10].  
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 1: Peroxisomes. Electron micrograph of an organelle pellet from a rat liver post-nuclear 
supernatant, kindly taken by Prof. Dr. Manuel Teixeira da Silva (IBMC). P, peroxisome; the arrow indicates 
the urate oxidase paracrystalline structure; scale bar = 1μM. 
 
Peroxisomes carry out several metabolic functions, being hydrogen peroxide 
metabolism [2, 11] and β-oxidation of fatty acids (long chain and very long chain) the 
main ones [12-14]. In animal cells they are also involved in several anabolic processes 
such as biosynthesis of plasmalogens and bile acids, catabolism of purines, 
polyamines and prostaglandins, α-oxidation of long chain and very long chain fatty 
acids and in the metabolism of some amino acids and glyoxylate [4, 15-21]. 
The functional diversity of peroxisomes is so extensive that in some organisms 
they are known by different names. For example, glyoxysomes are plant peroxisome-
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like organelles containing enzymes responsible for the glyoxylate cycle [22-25]; 
glycosomes in trypanosomatids possess most of the enzymes of the glycolytic pathway 
[26-28]; and in filamentous ascomycete fungi (e.g. Neurospora crassa), the Woronin 
bodies are specialized peroxisomes that function to seal the septal pores in response 
to cellular damage [29]. 
 
2. Peroxisomal Disorders 
 
Since peroxisomes are involved in numerous metabolic processes, it is not 
surprising that these organelles have an important and crucial role in human 
physiology. In fact, a number of distinct genetic diseases are associated with this 
organelle and are denominated peroxisomal disorders. These disorders have 
devastating consequences and are caused by the malfunction or even the absence of 
the peroxisome. Peroxisomal disorders are frequently divided into two groups: the 
single peroxisomal enzyme deficiencies and the peroxisomal biogenesis disorders [30-
34]. 
The single peroxisomal enzyme deficiencies are characterized by defects in a 
single peroxisomal enzyme/transporter, affecting a specific metabolic pathway such as 
ether-phospholipid synthesis, α- or β-oxidation of fatty acids or glyoxylate detoxification 
(Table 1) (reviewed in [33]). 
 
Table 1 – List of Single Peroxisomal Enzyme Deficiencies*. 
Disorder Deficient enzyme Metabolic pathway affected 
X-ALD Adrenoleukodystrophy protein Fatty acid β-oxidation 
Acyl-CoA oxidase deficiency Acyl-CoA oxidase 1 Fatty acid β-oxidation 
D-bifunctional protein deficiency D-bifunctional protein Fatty acid β-oxidation 
2-Methylacyl-CoA racemase deficiency 2-Methylacyl-CoA racemase Fatty acid β-oxidation 
Sterol carrier protein X deficiency Sterol carrier protein X Fatty acid β-oxidation 
RCDP type 3 DHAP acyltransferase Fatty acid β-oxidation 
RCDP type 2 Alkyl-DHAP synthase Ether-phospholipids synthesis 
Refsum disease Phytanoyl-CoA hydroxylase Fatty acid α-oxidation 
Hyperoxaluria type 1 Alanine:glyoxylate aminotransferase Glyoxylate detoxification 
Acatalasaemia Catalase H2O2 metabolism 
 
* Adapted from [33]. X-ALD, X-linked adrenoleukodystrophy; RCDP, rhizomelic chondrodysplasia 
punctata; CoA, coenzyme A; DHAP, dihydroxyacetone phosphate. 
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Peroxisomal Biogenesis Disorders (PBDs) are characterized by mutations in 
one of the many genes involved in proper peroxisome biogenesis, either in the 
membrane biogenesis, the matrix protein import pathway or division and proliferation 
[35, 36]. PBDs reflect a series of abnormalities due to the low number and size of 
peroxisomes or even the absence of normal organelles [10]. In cells of many PBD 
patients it is often possible to detect the so-called peroxisome “ghosts” [37]. These 
structures represent organelles with a normal repertoire of membrane proteins but 
possessing little or no matrix content [37]. Presently, the PEX genes responsible for 
PBDs are all known (Table 2). The association between the 13 genes and these 
disorders was possible due to cell fusion experiments using primary cultures of 
fibroblasts from PBD patients and also complementation analysis by transfection of 
fibroblasts with plasmids encoding different PEX proteins to restore peroxisome 
assembly [38-40]. 
 
                    Table 2 – PEX gene affected and clinical phenotypes*. 
Gene Clinical phenotypes 
PEX1 ZS, NALD, IRD 
PEX2 ZS, IRD 
PEX3 ZS 
PEX5 ZS, NALD 
PEX6 ZS, NALD, IRD 
PEX7 RCDP type 1 
PEX10 ZS, NALD 
PEX11β Mild ZS 
PEX12 ZS, NALD, IRD 
PEX13 ZS, NALD 
PEX14 ZS 
PEX16 ZS 
PEX19 ZS 
PEX26 ZS, NALD, IRD 
 
* Adapted from [40]. ZS, Zellweger syndrome; NALD, neonatal adrenoleukodystrophy; IRD, infantile 
Refsum disease; RCDP, rhizomelic chondrodysplasia punctata. 
 
The PBDs group includes disorders of the Zellweger spectrum and Rhizomelic 
Chondrodysplasia Punctata (RCDP) type 1 [32, 34]. The Zellweger spectrum includes 
the Zellweger syndrome (ZS), the neonatal adrenoleukodystrophy (NALD) and infantile 
Refsum disease (IRD), and these disorders have some overlapping symptoms such as 
liver disease, retinopathy and variable neurodevelopmental delay. One major 
difference between the three conditions regards the survival and phenotype severity of 
patients. The ZS is the most severe, with patients rarely surviving the first year, and 
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IRD is the milder one, with patients living over 30 years [30, 32]. In RCDP type 1 only 
some metabolic functions are lost, differing from the Zellweger spectrum in its 
biochemical and molecular basis and clinical presentation. In fact, this disease is 
characterized by mutations in only one gene that encodes PEX7, whereas the 
Zellweger spectrum is caused by mutations in any of the remaining PEX genes [32, 
41]. 
 
3. Peroxisome Biogenesis 
 
As refered earlier, peroxisomes have no DNA and therefore peroxisomal 
proteins are encoded by nuclear DNA, synthesized on cytosolic ribosomes and post-
translationally targeted to the organelle [3, 42-44]. 
Identification of PEX genes started with studies in Saccharomyces cerevisiae 
and were applied to a variety of organisms such as Pichia pastoris, Hansenula 
polymorpha and Yarrowia lipolytica [45-50]. These studies allowed the identification of 
the majority of known peroxisome biogenesis-associated genes. The mammalian 
homologs were then identified by homology probing approaches [51]. Over 30 peroxins 
have been identified among several organisms [52, 53], but only sixteen were reported 
in mammals (Table 3) [54]. Most of these proteins are conserved between species but 
depending on the organism some specific roles were embraced by a single peroxin [53, 
54]. 
Peroxisomal biogenesis is generally divided into three processes: peroxisome 
membrane biogenesis, import of matrix proteins into the organelle and peroxisome 
proliferation. A brief description of each of these processes is provided below. 
 
3.1 Peroxisomal Membrane Biogenesis 
 
The origin of the peroxisomal membrane is a subject of some controversy in the 
field [55, 56]. Several studies support a model in which peroxisomes are regarded as 
autonomous organelles deriving from pre-existing ones by growth and division [57-59]. 
The phospholipid requirements are fulfilled by the endoplasmic reticulum (ER) [55]. 
However, some authors claim that the ER is involved in the de novo formation and 
maintenance of peroxisomes, producing vesicles (protoperoxisomes) that eventually 
mature into peroxisomes or fuse with pre-existing organelles [57]. 
Targeting of newly synthesized peroxisomal intrinsic membrane proteins 
(PMPs) to the organelle requires signals, designated membrane peroxisomal targeting 
signals (mPTS), which are characterized by a cluster of basic aminoacids and a 
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transmembrane domain anchoring the protein to the peroxisomal membrane [60, 61]. 
These signals are quite different from the ones in proteins to be imported into the 
matrix of the organelle (see section 3.3).  
 
Table 3 – Proteins implicated in peroxisomal biogenesis (peroxins). 
Peroxin Organisms Localization Domains Proposed function 
PEX1 M, P, F, Y membrane (cytosol) AAA ATPase Matrix protein import, export of PEX5 
PEX2 M, P, F, Y membrane Zinc RING finger Matrix protein import 
PEX3 M, P, F, Y membrane  Membrane biogenesis, PMP import 
PEX4 P, F, Y membrane (cytosol) 
E2 Ubiquitin- 
conjugating enzyme 
Matrix protein import, ubiquitination of PEX5
PEX5a M, P, F, Y cytosol/membrane 
Natively unfolded  
domain, TPRs 
Matrix protein import, PTS1 (and PTS2 in 
M, P) receptor 
PEX6 M, P, F, Y membrane (cytosol) AAA ATPase Matrix protein import, export of PEX5 
PEX7 M, P, F, Y cytosol/membrane WD repeats Matrix protein import, PTS2 receptor 
PEX8 F, Y membrane (matrix)  Matrix protein import 
PEX9 Yl (ORF  misidentified,    antisense sequence of  PEX26) 
PEX10 M, P, F, Y membrane Zinc RING finger Matrix protein import 
PEX11b M, P, F, Y membrane  Division and proliferation 
PEX12 M, P, F, Y membrane Zinc RING finger Matrix protein import 
PEX13 M, P, F, Y membrane SH3 Matrix protein import 
PEX14 M, P, F, Y membrane Coiled-coil Matrix protein import 
PEX15 Sc membrane  Matrix protein import, PEX1/PEX6 anchor 
PEX16 M, P, F, Yl membrane  Membrane biogenesis 
PEX17 Y membrane Coiled-coil Matrix protein import 
PEX18 Sc cytosol/membrane  Matrix protein import, PTS2 import 
PEX19 M, P, F, Y cytosol/membrane Farnesylation motif Membrane biogenesis, PMP import 
PEX20 F, Y cytosol/membrane  Matrix protein import, PTS2 import 
PEX21 Sc cytosol/membrane  Matrix protein import, PTS2 import 
PEX22 P, F, Y membrane  Matrix protein import, PEX4 anchor 
PEX23 F, Y membrane Dysferlin Proliferation 
PEX24 F, Y membrane  Proliferation 
PEX25 Y membrane  Proliferation 
PEX26 M, F, Yc membrane  Matrix protein import, PEX1/PEX6 anchor 
PEX27 Sc membrane  Proliferation 
PEX28 Sc membrane  Proliferation (PEX24 ortholog) 
PEX29 Y membrane  Proliferation 
PEX30 Sc membrane Dysferlin Proliferation (PEX23 ortholog) 
PEX31 Sc membrane Dysferlin Proliferation 
PEX32 Y membrane Dysferlin Proliferation 
M, mammals; P, plants; F, filamentous fungi, Y, yeasts, Yl, Yarrowia lipolytica only; Sc, Saccharomyces cerevisiae only; 
aMammals contain two main isoforms, PEX5S and PEX5L, the later harbouring a PEX7-binding site; bMammalian cells 
contain three PEX11 genes encoding PEX11α, PEX11β and PEX11γ; cPEX26 is absent in Sc and related yeasts. 
PEX1, PEX4 and PEX6 are peripheral membrane proteins facing the cytosol. PEX8 is a peripheral membrane protein 
facing the peroxisomal matrix. Colour coding is according to the involvement of peroxins in peroxisomal biogenesis 
pathways, i.e., membrane assembly (violet), import of matrix proteins (blue) and growth and division (green). AAA 
ATPase, ATPase associated with several cellular activities; RING, Really interesting new gene; WD, Tryptophan-
aspartate motif; TPRs, tetratricopeptide repeats; SH3, Src-homology 3 domain; ORF, open reading frame. 
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Membrane biogenesis in mammals and other organisms requires three 
peroxins: the intrinsic membrane proteins, PEX3 and PEX16, and a 
cytosolic/membrane protein, PEX19 [62, 63]. Most PMPs interact with their receptor 
PEX19 in the cytosol during or right after their translation, guaranteeing an import-
competent status. Therefore, PEX19 acts as a chaperone for membrane proteins 
probably by protecting their hydrophobic domains [64-69]. PEX3 is the docking protein 
at the peroxisomal membrane for the PEX19-PMP complexes [70-72] and may also 
promote the insertion of PMPs into the peroxisomal membrane [73]. As for PEX16, its 
role remains poorly understood [63] but some authors state that PEX16 promotes the 
peroxisomal growth from the ER [74, 75]. 
 
 
3.2 Peroxisome proliferation 
 
Peroxisomes are organelles characterized by their metabolic plasticity, being 
able to adjust to different physiological requirements [76, 77]. In mammals, the PEX11 
family is involved in peroxisome proliferation and comprises three proteins: PEX11α, 
PEX11β and PEX11γ [7, 78, 79]. Loss of these proteins will lead to a reduction in 
peroxisomal number and presence of large peroxisomes [40, 80]. 
Peroxisome proliferation involves growth, elongation and a final step of division 
(reviewed in [81]). PEX11 is responsible for peroxisome elongation while the final 
membrane fission is performed by a dynamin-like protein (DLP1) [57, 58]. DLP1 
anchors at the peroxisomal membrane through Fis1, a C-tail anchored protein [82]. 
These last two proteins, required for peroxisome proliferation, are also involved in 
mitochondria division [83]. 
 
 
3.3 Peroxisome matrix protein import 
 
Peroxisomal matrix is the place of higher protein concentration in eukaryotic 
cells [84]. More than 50 different enzymes can be found in the matrix of the organelle 
[3, 21]. Similarly to the membrane biogenesis, the matrix protein import involves 
targeting sequences, cytosolic receptors and a membrane machinery to promote the 
internalization of these proteins. 
Regarding the targeting signals, peroxisomal matrix proteins are sorted via one 
of two pathways. The majority of proteins present a Peroxisomal Targeting Signal type 
1 (PTS1), a C-terminal tripeptide with the consensus sequence (S/A/C) – (K/R/H) – 
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(L/M) [85-87]. However, residues upstream from the PTS1 signal can also influence the 
interaction between the receptor and the cargo protein [87, 88]. PEX5 is the receptor 
for PTS1-containing proteins and the PTS1 recognition site is at its C-terminal half [89-
92]. The second PTS signal (PTS2) is a N-terminal degenerate nonapeptide consisting 
of the consensus sequence (R/K) – (L/V/I) – (X)5 – (H/Q) – (L/A). Only a small number 
of proteins possess a PTS2 signal and after internalization it is cleaved from the matrix 
protein [93-95]. PEX7 is the receptor for these PTS2 proteins [96, 97] but accessory 
proteins are needed to assist the delivery of these cargoes to the peroxisome [93, 98]. 
These proteins are species-specific: PEX18/PEX21 in S. cerevisiae [99] and PEX20 in 
the majority of yeast and fungi [100, 101]. In mammals and plants, PEX7 uses PEX5 
itself for the targeting of PTS2-proteins to the peroxisome [102-104].  
 
 
3.3.1 – PEX5 
 
PEX5 was initially identified in P. pastoris and subsequently found in all 
peroxisome-containing organisms (revised in [4]). In mammals, two isoforms are found 
due to alternative splicing of the PEX5 transcript: a large isoform, PEX5L, and a small 
one, PEX5S. PEX5L comprises 639 amino acids while the smaller isoform lacks an 
internal sequence of 37 amino acids, encoded by exon 8 [91, 105, 106]. This small 
region comprises the domain that interacts with PEX7, the PTS2 receptor, but this 
interaction is only observed in plants and mammals [102-105, 107, 108].  
PEX5 can be divided in two distinct domains based on structural/functional 
data: the N-terminal and the C-terminal halves (Figure 2). A highly conserved C-
terminal domain can be found when aligning PEX5 sequences, while the N-terminal 
half reveals low conservation between several organisms (Figure 3). 
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Figure 2: PEX5. Schematic presentation of the domain structure of human PEX5L and interaction sites for 
known components of the peroxisomal import machinery. The purple bars indicate the diaromatic motifs 
(WxxxF/Y PEX14 binding sites). The blue area indicates the extra 37 aminoacid encoded by exon 8 which 
contains the PEX7 binding site and is absent in the small isoform of PEX5. The red boxes represent the 
TPR domains. TPR, tetratricopeptide repeats. 
 
The N-terminal half of PEX5 is a natively unfolded domain [109]. PEX5, being a 
monomeric protein, displays a flexible N-terminal half, being characterized by an 
unusually large Stokes radius and a small sedimentation coefficient [110]. Natively 
unfolded proteins/domains are frequently involved in protein-protein interactions with 
multiple partners [111]. Indeed, the N-terminal domain of PEX5 is characterized by the 
existence of several domains of interaction with other peroxins. Seven pentapeptide 
diaromatic motifs WXXXF/Y are present in this PEX5 domain and are responsible for 
the interaction with PEX14 and PEX13, two members of the Docking/Translocation 
Machinery (DTM) [112-119]. As previously mentioned, the N-terminal half of PEX5 
harbours the PEX7 interaction site. Besides binding to PEX7, some observations also 
show that the N-terminal half of PEX5 also interacts with some cargo proteins [120, 
121]. The C-terminal domain of PEX5 contains seven tetratricopeptide repeats (TPRs) 
with a highly conserved structure, consisting of two clusters, TPRs 1-3 and TPRs 5-7, 
connected by a flexible hinge comprising TPR4. These TPRs are involved in the 
interaction with PTS1-containing proteins. This property was confirmed with studies 
showing PEX5 interacting with SKL-containing peptides or a PTS1 cargo protein 
(Figure 4) [122-126]. When PEX5 interacts with a PTS1 protein, a ring-like structure is 
formed by the two TPR clusters with the PTS1 peptide occupying the center of this 
ring-like structure. In the absence of a cargo protein there is a slight opening of the 
ring-like structure. 
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Hs   MAMRELVEA---ECGGA------NPLMKLAGHFTQDKALRQE-------GLRPGPWPPGAPASEAASKPLGVAS   58 
Dr   MAMRELVEA---ECGGA------NPLMKLTGHMTQEGGAWRH-------RSTP-TIPP---------TPIEIAT   48 
Ce   --MKGVVEG---QCGQQ------NALVGLANTFGTSNQRVAP-------SNAAASLLP------------SSSM   44 
At   MAMRDLVNGGAA-CAVPGSSSSSNPLGALTNALLGSSSKTQERLKEIPNANRSGPRPQFYSEDQQIRSLPGSEL   73 
Sc   MDVGS--------CSVG-----NNPLAQLHKHTQQNKSLQFNQ-KNNGRLNESPLQGTNKPGISEAFISNVNAI   60 
       :     .    *         *.*  *      .                .         
 
Hs   EDELVAEFLQDQNAPLVSRAPQTFKMDDLLAEMQQIEQS----------------------------------    97 
Dr   EDELVAEFLQGP-----QRPPHSFDMGQLLEEMQQIDQQ----------------------------------    82 
Ce   GEQMANEFLRQQAR---TMAPTSFSMKSMQNNLPQAS------------------------------------    78 
At   DQPLLQPGAQGSEFFRGFRSVDQNGLGAAWDEVQQGGPMPPMGPMFEPVQPTFEGPPQRVLSNFLHSFVESSR    146 
Sc   SQENMANMQRFINGEPLIDDKRRMEIGPSSGRLPPFSNVHS--------------------------------    101 
      :       :               :     .:                                         
 
Hs   -----------------NFRQAPQRAPGVADLALSENWAQEFL-AAGDAVDVT----QDYN------------    136 
Dr   -----------------NYRQAPQRAPDVAALALSGDWASEFL-STADAASSSGQAALDPA------------    125 
Ce   -----------------------------ASSSLAANWTKEFQ-PRQNQLASQ--------------------    101 
At   GGIPFRPAPVPVLGLSQSDKQCIRDRSSIMARHFFADRGEEFINSQVNALLSSLDIDDGIQARGHVPGRFREL    219 
Sc   -------------------LQTSANPTQIKGVNDISHWSQEFQ--GSNSIQNRNADTGNSE------------    141 
                                         .  .**     :                          
 
Hs   -----------------ETDWSQEFISEVTDPLSVSPARWAEEYLEQSEEKLWLGEPEG------TATDR-WY    185 
Dr   -----------------DADWTREFINEVAD-----PGRWAEEYLEQSEEKLWLGDLGE------REQDKEWA    170 
Ce   --------------------WSQQYTSSAPS-------------MESAWRQVQAPSMTS------TSSHQPIT    135 
At   DDYWNESQAVVKPNLHPADNWAAEFNQHGMDHG--GPDSWVQSFEQQHGVNGWATEFEQGQSQLMSSQMRSMD    290 
Sc   ------------------KAWQRGSTTASSRFQY--PNTMMNNYAYASMNSLSGSRLQSPAFMNQQQSGRSKE    194 
                         *                             .                  :    
 
Hs   DEYHPEEDLQHTASDFVAKVDDPKLANSEFLKFVRQIGEGQVSLESGAGSGRAQAEQWAAEFIQQQGTSDAWV    258 
Dr   QEYQSGEELRQTANELVAKVDDPKLQN------------TEVSAES----------------------AESWV    209 
Ce   DAGMWSSEYLDTVDTSLTKSSG----------------------------------------------TQNWA    162 
At   MQNIAAMEQTRKLAHTLSQDGNPKFQNSRFLQFVSKMSRGELIIDENQVKQASAPGEWATEYEQQYLGPPSWA    363 
Sc   GVNEQEQQPWTDQFEKLEKEVSENLDIN------------------------------------DEIEKEENV    231 
            :        : :  .                                                  . 
 
Hs   DQFTRPVNTSA------------LDMEFERAKSAIESDVDFWDKLQAELEEMAKRDAEAHPWLSDYDDLTS--    317 
Dr   DEFAT------------------YGPDFQQAKAAVESDVDFWEKLQQEWEEMAKRDAEAHPWLSDFDQMLS--    262 
Ce   DDFME-----------------------QQDNYGMENTWKDAQAFEQRWEEIKR----------DMEKDES--    200 
At   DQFANEKLSHGPEQWADEFASGRGQQETAEDQWVNEFSKLNVDDWIDEFAEGPVGDSSADAWANAYDEFLNEK    436 
Sc   SEVEQNKPETVE------------KEEGVYGDQYQSDFQEVWDSIHKDAEEVLPSELVNDDLNLGEDYLKYLG    292 
     .:.                            .   .      :       *               :       
 
Hs   ---ATYDKGYQFEEENPLRDHPQPFEEGLRRLQEGD-LPNAVLLFEAAVQQDPKHMEAWQYLGTTQAENEQEL    386 
Dr   ---SSYDKGYQFEEDNPYLSHEDPFAEGVKRMEAGD-IPGAVRLFESAVQRQPDNQLAWQYLGTCQAENEQEF    331 
Ce   ---LQSPENYVYQEANPFTTMSDPLMEGDNLMRNGD-IGNAMLAYEAAVQKDPQDARAWCKLGLAHAENEKDQ    269 
At   NAGKQTSGVYVFSDMNPYVGHPEPMKEGQELFRKGL-LSEAALALEAEVMKNPENAEGWRLLGVTHAENDDDQ    508 
Sc   -GRVNGNIEYAFQSNNEYFNNPNAYKIGCLLMENGAKLSEAALAFEAAVKEKPDHVDAWLRLGLVQTQNEKEL    364 
              * :.. *      :.   *   :. *  :  *    *: * ..*..  .*  **  :::*:.: 
 
Hs   LAISALRRCLELKPDNQTALMALAVSFTNESLQRQACETLRDWLRYTPAYAHLVTPAEEGAGGAGLGPSKR--    457 
Dr   AAISALRRCIELKKDNLTALMALAVSFTNESLHRQACETLRDWLMHNPKYRIILEQHEREKQREGAREREKES    404 
Ce   LAMQAFQKCLQIDAGNKEALLGLSVSQANEGMENEALHQLDKWMSSYLGSNSTQVTTTPP-------------    329 
At   QAIAAMMRAQEADPTNLEVLLALGVSHTNELEQATALKYLYGWLRNHPKYGAIAPP-----------------    564 
Sc   NGISALEECLKLDPKNLEAMKTLAISYINEGYDMSAFTMLDKWAETKYPEIWSRIKQQDDKFQ----------    427 
      .: *: .. : .  *  .:  *.:*  **  .  *   *  *                        
 
Hs   -ILGSLLSDSLFLEVKELFLAAVRLDPTSIDPDVQCGLGVLFNLSGEYDKAVDCFTAALSVRPNDYLLWNKLG    529 
Dr   ERFGSLLPEALFGEVQTLFLNAAAAEPSQVDPELQCGLGVLFNLSGEYDKAVDCFSAALSVTPQDYLLWNKLG    477 
Ce   -LYSSFLDSDTFNRVEARFLDAARQQGATPDPDLQNALGVLYNLNRNFARAVDSLKLAISKNPTDARLWNRLG    401 
At   ----ELADSLYHADIARLFNEASQLNPE--DADVHIVLGVLYNLSREFDRAITSFQTALQLKPNDYSLWNKLG    631 
Sc   -KEKGFTHIDMNAHITKQFLQLAN-NLSTIDPEIQLCLGLLFYTKDDFDKTIDCFESALRVNPNDELMWNRLG    498 
          :        :   *      :    *.:::  **:*:  . :: ::: .:  *:   * *  :**:** 
 
Hs   ATLANGNQSEEAVAAYRRALELQPGYIRSRYNLGISCINLGAHREAVEHFLEALNMQRKS---------RGPR    593 
Dr   ATLANGNRSEEAVAAYRRALELQPGFVRSRYNLGISCVNLGAHREAVEHFLEALSLQRQAAGDGEAGAGRGPG    550 
Ce   ATLANGDHTAEAISAYREALKLYPTYVRARYNLGISCMQLSSYDEALKHFLSALELQKGG-------------    461 
At   ATQANSVQSADAISAYQQALDLKPNYVRAWANMGISYANQGMYKESIPYYVRALAMNPKA-------------    691 
Sc   ASLANSNRSEEAIQAYHRALQLKPSFVRARYNLAVSSMNIGCFKEAAGYLLSVLSMHEVN----TNNKKGDVG    567 
     *: **. :: :*: **:.**.* * ::*:  *:.:*  : . . *:  : : .* ::       
 
Hs   GEGGAMSENIWSTLRLALSMLG--QSDAYGAADA-RDLSTLLTMFGLPQ----    639 
Dr   AAATIMSDNIWSTLRMALSMMG--ESSLYSAADR-RDLDTLLTHFSHREGEAE    600 
Ce   ----NDASGIWTTMRSAAIRTSNVPDNLLRAVER-RDLAAVKASLV-------    602 
At   -------DNAWQYLRLSLSCAS--RQDMIEACES-RNLDLLQKEFPL------    728 
Sc   SLLNTYNDTVIETLKRVFIAMN--RDDLLQEVKPGMDLKRFKGEFSF------    612 
         .   ::      .   ..     .   :*  .   :      
 
Figure 3: Sequence alignment of PEX5 proteins (ClustalW2, www.ebi.ac.uk). The long isoform of 
human (Hs) PEX5 is aligned with homolog proteins from Danio rerio (Dr), Caenorhabditis elegans (Ce), 
Arabidopsis thaliana (At) and Saccharomyces cerevisae (Sc). Red colour marks the WXXXF/Y diaromatic 
motifs located at PEX5 N-terminal half. 
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      PEX5(C)                                             PEX5(C)                                             PEX5(C) 
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Figure 4: Structures of the C-terminal half of PEX5 (PEX5(C)). The structures were obtained in the 
absence of a ligand (left, [123]) in the presence of the consensus PTS1 peptide YQSKL (Protein Data 
Base accession number 1FCH) (central, [122]) or in the presence of the functional PTS1 cargo protein 
SCP2 (right, [123]). Colour coding: TPR segments 1–3, light green; TPR4 segment, dark green; TPR 
segments 5–7, blue; loop connecting the TPR segment and the C-terminal helical bundle, yellow; C-
terminal α-helical bundle, red; PTS1 ligands, black. Adapted from [123]. 
 
3.3.2 – The Cycling Receptor Model 
 
PEX5 presents a dual subcellular localization. Elegant studies demonstrated 
that PEX5 can accumulate at the peroxisomal membrane when temperature and ATP 
levels are experimentally decreased [127]. Moreover, the peroxisomal accumulation of 
PEX5 is completely reversible suggesting that PEX5 can undergoe multiple cycles of 
association/dissociation. Knowing that PEX5 recognizes and binds cargo proteins, it 
was proposed that this protein is a cycling receptor [127]. According to this model, 
matrix proteins are recognized by PEX5 in the cytosol, are directed to the peroxisomal 
membrane, translocated to the matrix of the organelle and finally PEX5 is recycled 
back into the cytosol. 
Understanding how the peroxisomal import machinery works requires 
knowledge on the arquitecture of its components. Over the years, numerous studies 
have addressed this issue. Using biochemical (e.g., pull-down assays, 
immunoprecipitation experiments and protein purification techniques) and genetic 
approaches (e.g., yeast two-hybrid) it was possible to build models on the structure of 
the Peroxisomal Import Machinery (PIM) (Figure 5) [128-132]. In mammals, this 
machinery comprises: 1) a membrane-embedded DTM that includes PEX14, PEX13 
and the Really Interesting New Gene (RING)-finger peroxins PEX2, PEX10 and 
PEX12; and 2) a Receptor Export Module (REM) that includes the two ATPases 
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Associated with diverse Activities (AAA) peroxins, PEX1 and PEX6, and their 
membrane anchor, PEX26. Besides these peroxins, the PIM also includes ubiquitin, an 
ubiquitin-activating enzyme (E1) and an ubiquitin-conjugating enzyme (E2).  
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Figure 5: Components of the peroxisomal import machinery (PIM).  Peroxins absent in mammals (M) are depicted 
in gray. Receptors and co-receptors of cargo proteins are represented. The docking/translocation module comprises 
mostly transmembrane proteins. PEX8 and PEX17 have been found only in lower eukaryotes [53, 54]. The first two 
reactions of the ubiquitin-conjugating cascade involved in the peroxisomal protein import pathway are shown. Note that 
in mammals the E2 component is a cytosolic protein whereas in plants, yeasts and fungi the E2 PEX4 is bound to the 
organelle membrane via PEX22. The precise identity of the final component of this cascade, ie, the ubiquitin-ligase 
catalyzing mono-ubiquitination of PEX5 remains unknown but it may be any of the 3 RING peroxins of the DTM or 
combinations of them. The receptor export module comprises AAA peroxins PEX1 and PEX6 and one intrinsic 
membrane protein anchor [133, 134], PEX26 in mammals and other organisms, and PEX15 in some yeasts. PEX26 and 
PEX15 are unrelated at the primary structure level [53]. Their plant functional counterpart is presently unknown [135]. 
Adapted from [136]. 
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Using an in vitro import system, our laboratory has provided valuable data 
regarding the mammalian PEX5-mediated peroxisomal protein import pathway. This 
system is based in the incubation of radiolabeled PEX5 or a PTS2-containing protein 
with a rat liver post-nuclear supernatant (PNS) under appropriate experimental 
conditions. A protease-protection assay is then performed to evaluate the specificity of 
the process, since non-peroxisomal PEX5 or non-imported cargo protein are 
susceptible to proteolytic cleavage. The model presented in Figure 6 accommodates all 
the data gathered so far regarding this pathway. The model comprises several steps 
(numbered 0-4) as detailed below. 
First, soluble PEX5 (stage 0) binds to cargo proteins in the cytosol yielding 
stage 1a PEX5. It is possible that this interaction somehow changes the conformation 
of PEX5 because the receptor only engages the next steps (i.e., interaction with the 
DTM) if cargo proteins are available [137]. The cytosolic cargo-loaded PEX5 then 
interacts with the DTM yielding stage 1b. There are some data suggesting that the 
docking site for the complex at the peroxisomal membrane is PEX13 and/or PEX14 
although convincing data for these possibilities are still lacking [138, 139]. Once at the 
peroxisomal membrane, cargo-loaded PEX5 becomes inserted into the DTM (stage 2), 
acquiring a transmembrane topology with a small N-terminal domain exposed to 
cytosol and protease accessible [140], whereas the bulky fraction of PEX5 polypeptide 
chain can only be accessed by the matrix of the organelle [140]. Strikingly, the 
transition between stage 1b and stage 2 PEX5 is an ATP-independent process [137, 
141, 142]. Next, the DTM-embedded PEX5 is monoubiquitinated at a conserved N-
terminal cysteine residue (Ub-PEX5, stage 3, completely protease-resistant) [143, 144]. 
The evidence supporting the importance of the cysteine residue is several fold: deletion 
of the 17 amino acid domain containing this cysteine, its alkylation or its substitution by 
a serine or alanine results in PEX5 proteins still functional in the docking and 
membrane insertion steps but export-incompetent [142, 144, 145]. Monoubiquitination 
is a mandatory event for the export of PEX5, an event that is ATP-dependent [144]. 
PEX1/PEX6 endorse this export step, where Ubiquitin-PEX5 (Ub-PEX5) is recognized 
and extracted from the peroxisomal membrane back into the cytosol, yielding a soluble 
Ub-PEX5 conjugate (stage 4) [134, 146]. Finally, the ubiquitin moiety is removed from 
the Ub-PEX5 conjugate, a process that possibly occurs by a combination of enzymatic 
and non-enzymatic mechanisms [147, 148]. In mammals, it was recently shown that 
USP9X is by far the most active deubiquitinase (DUB) acting on Ub-PEX5 [149]. 
All the data mentioned so far was obtained using a PEX5-centered in vitro 
import system. However, this approach gave us no information about the cargo 
insertion into the DTM and its release into the organelle matrix. Recent findings from 
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our laboratory came to elucidate these matters. Indeed, using a PTS2-centered in vitro 
import system [150], it was possible to conclude that PTS2-cargo insertion into the 
DTM occurs at the stage 1b-to-stage 2 transition, as previously hypothesized [151] and 
that the release of the reporter protein to the organelle matrix occurs before 
ubiquitination of PEX5.   
 
 
4. – Oligomeric matrix protein import 
 
Peroxisomes can be distinguished from other organelles by their ability to 
import proteins in their oligomeric state (reviewed in [3]). However, this has been a 
controversial subject during the past years. On one hand, some work has been 
published stating that protein oligomerization occurs after import into the peroxisome: 
Lazarow and de Duve showed that catalase was imported as a monomer [152, 153] 
and the same was observed in cucumber glyoxysomes for malate synthethase import 
[154]; finally alcohol oxidase octomerization was shown to occur during or right after 
import to the peroxisomes [155-157]. On the other hand, several authors claim that 
peroxisomes have the ability to import proteins in their native state. It was shown that a 
peroxisomal protein lacking a PTS1 signal can form a complex with a PTS1-containing 
protein and enter the organelle. This phenomenon is designated “piggy-back” import. 
The first evidences supporting this idea came from studies where a N-terminal 
truncated version of thiolase, lacking the PTS2 signal, was found to be imported in 
complex with a full-length version of itself [158]. Another example comes from the work 
with chloramphenicol acetyltransferase. Those authors proposed that subunits of this 
protein, lacking the PTS1 signal, were able to form heterotrimers with subunits 
containing a PTS1 in the cytosol and be targeted to the peroxisome [159]. The same 
phenomenon was reported for other proteins like Mdh3 from S. cerevisiae [85], 
isocitrate lyases of some plants [160] and enoyl-CoA isomerases Dci1p and Eci1p from 
S. cerevisiae [161]. In a different experimental setting, Walton and collaborators 
microinjected mammalian cells with gold particles (with a diameter ranging from 4-9 
nm) coated with human serum albumin conjugated with a PTS1 signal [162]. They 
observed that these particles could be imported into the peroxisomal matrix.  
 
 
 
 
 
 
I. INTRODUCTION 
15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: The PEX5-mediated peroxisomal protein import pathway in mammals. The matrix protein 
import pathway comprises five major steps (numbered 0-4). Stage 0, cytosolic cargo-free PEX5 (protease 
accessible). Stage 1, cytosolic PEX5-cargo protein complex (protease accessible). Stage 2, PEX5 
embedded in the peroxisomal docking/translocation machinery (DTM) (only 2 kDa of PEX5 N-terminus are 
accessible to exogenously added Proteinase K). Stage 3, DTM-embedded monoubiquitinated PEX5 at 
Cys11 (protease protected). Stage 4, protease accessible monoubiquitinated PEX5. 8,indicates reagents 
that block the pathway at specific steps; CP, cargo protein; Ub, ubiquitin; IAA, iodoacetamide; rTPR, 
recombinant protein comprising the PTS1-binding domain of PEX5; rPEX5, recombinant full-length PEX5; 
REM, receptor export module. Adapted from [150]. 
 
 
These observations come together to illustrate the ability of peroxisomes to 
import: 1) proteins in their native state, 2) oligomeric proteins and 3) large structures 
([158, 159], reviewed in [3]). However, the import kinetics of a given cargo protein has 
never been truly studied. In fact, there is only one study where this issue was 
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considered. Goodman and co-workers showed that the import kinetics of the trimeric 
chloramphenicol acetyltransferase is strangely slow, taking hours to occur [159], in 
contrast with the import of authentic peroxisomal proteins which, for all cases analyzed 
so far, occurs in minutes [152, 153, 155, 163]. The import of oligomeric proteins shows 
that the DTM is quite flexible, which is expected since it allows the import of monomeric 
proteins with different sizes, like glutathione S-transferase kappa 1 (25 kDa) or Lon-
protease (105 kDa). Neverthless, it remains to be clarified if the import of oligomeric 
proteins represents a bona fide mechanism used under normal physiological conditions 
or simply a residual activity of the peroxisome import machinery.  
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Understanding the PEX5-mediated protein import pathway requires knowledge 
on how this peroxin binds cargoes in the cytosol and releases them in the peroxisomal 
matrix. 
The aims of the work were: 
 
- to characterize the interaction of PEX5 with cargo proteins using a biologically 
relevant experimental set-up; 
 
- to determine whether the PEX5-cargo protein interaction can be disrupted by 
some DTM components; 
 
- to characterize the peroxisomal import efficiency of a cargo protein in its 
monomeric and oligomeric state. 
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1. Primer list 
 
Table 4: Primers used in DNA manipulations 
 
Protein Primers  
Fw - GAGCGCGCCATATGGCAGACTTGGCCTTGTCT PEX5∆N110 
Rv* - GCGTAATTAAGCTTGGCTGCAGGTC 
PEX5∆N147 Fw - GAGCGCGCCATATGGTTACAGACCCCTTGTCTG 
PEX5∆N196 Fw - GAGCGCGCCATATGACGGCCAGTGACTTTGTG 
PEX5∆N267 Fw - GAGCGCGCCATATGTCTGCCCTTGATATGGA 
PEX5∆N290 Fw - GAGCGCGCCATATGTTGCAGGCAGAGTTGGA 
Fw - GCTGAGGCCCACCCCGCTCTTTCTGACTATGAT W308A 
Rv - ATCATAGTCAGAAAGAGCGGGGTGGGCCTCAGC 
Fw - CCGCTCTTTCTGACGCTGATGACCTTACG 
PEX5∆N267-M7 ; 
 PEX5-M7 
Y312A 
Rv - CGTAAGGTCATCAGCGTCAGAAAGAGCGG 
Fw - TACATCAGATGCCGCGGTTGACCAGTTCAC W257A 
Rv - GTGAACTGGTCAACCGCGGCATCTGATGTA 
Fw - CCGCGGTTGACCAGGCCACAAGACCAGTAA 
PEX5M6,7** 
F261A 
Rv - TTACTGGTCTTGTGGCCTGGTCAACCGCGG 
Fw - GCGAACTGCATATGGCAATGCGGGAGCTGG PEX5 (Mus musculus) 
Rv - GCGGTCGACTCACTGGGGCAGGCCAAACAT 
Fw - GGTCTAGAGCCACCATGGCTGACAGCC Catalase 
Rv - GGTACCCCTCACAGATTTGCCTTCT 
Fw - ACTTGGCGGCAAGGGAGTAGGCAAATCTGTGA Cat∆KANL 
Rv - TCACAGATTTGCCTACTCCCTTGCCGCCAAGT 
Fw - CGGCAAGGGAGGAGGACTAACTGTGAGGTACCGA CatED 
Rv - TCGGTACCTCACAGTTAGTCCTCCTCCCTTGCCG 
Fw - GCTAATTCTAGAGCCACCATGAATCCCGATCTG AOX 
Rv - CGCCGTGGTACCTAGCATCAAAGCTTCGACTG 
Fw - GCAGCATCTAGAGCCACCATGGCCCATTACC UOX 
Rv - CGCGCGGGTACCTTTCACAGCCTGGAAGGCA 
Fw - GCGCCGTCTAGAGCCCATTACCATGACAACT 2HA-UOX 
Rv - CGCGCGGGTACCTTTCACAGCCTGGAAGGCA 
 
* The same reverse primer was used for PEX5∆N110, PEX5∆N147, PEX5∆N196, 
PEX5∆N267 and PEX5∆N290. 
** This plasmid encoding PEX5-M7 was used as the template for this mutagenesis.  
Cat, catalase; AOX, acyl-CoA oxidase; UOX, urate oxidase; Fw, forward primer; Rv, 
reverse primer. 
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2. Production and expression of recombinant proteins 
 
The recombinant large isoform of human PEX5 [91, 105], a protein comprising 
the first 324 amino acid residues of PEX5 (ΔC1PEX5), a protein containing amino acid 
residues 315-639 of PEX5 (TPRs), PEX5 containing the missense mutation N526K 
(PEX5N526K), a protein comprising the first 80 amino acid residues of human PEX14 
(NDPEX14) and full-length PEX19 (PEX19) were obtained as previously described [64, 
109, 110, 145, 164].  
The following His-tagged truncated versions of human PEX5 were also 
produced: PEX5ΔN110 (amino acid residues 111-639 of PEX5), PEX5ΔN147 (amino 
acid residues 148-639 of PEX5), PEX5ΔN196 (amino acid residues 197-639 of PEX5), 
PEX5ΔN267 (amino acid residues 268-639 of PEX5) and PEX5ΔN290 (amino acid 
residues 291-639 of PEX5). The cDNAs encoding these proteins were obtained by 
PCR using the primers listed in Table 4, and the pQE30-PEX5 [110] construct as 
template. The amplified DNA fragments were then digested with NdeI and SalI and 
cloned into the NdeI/SalI digested pET-28c vector (Novagen). Expression of these 
truncated versions of PEX5 was performed in the BL21 (DE3) strain of Escherichia coli 
(E. coli). 
The QuickChange® Site-Directed Mutagenesis Kit (Stratagene) was used to 
replace tryptophan and phenylanaline/tyrosine residues by alanines in diaromatic 
motifs of PEX5 (see primers in Table 4). The three proteins obtained in this way are: 
PEX5ΔN267-M7 and PEX5-M7, proteins with a mutated 7th diaromatic motif; and 
PEX5-M6,7, a protein possessing both the 6th and 7th diaromatic mutated. Expression 
of these mutated versions of PEX5 was performed in the BL21 (DE3) strain of E. coli. 
In order to obtain the His-tagged mouse PEX5, its cDNA was amplified from a 
commercially available clone (clone MMM1013-7510385, Open Biosystems) using the 
primers listed in Table 4, digested with NdeI and SalI and cloned into the NdeI/SalI 
digested pET-28c vector. Expression of this protein was performed in the BL21 (DE3) 
strain of E. coli. 
All plasmids were sequence verified. Purification of all PEX5 proteins was 
performed as described [110]. 
 
3. Plasmids for the synthesis of 35S-radiolabeled proteins 
 
The cDNAs encoding full-length human catalase (Cat) (clone IMAGE ID 
5551309, Open Biosystems), full-length mouse acyl-CoA oxidase (AOX) (clone IMAGE 
ID 5704873,Open Biosystems) and full-length mouse urate oxidase (UOX) (clone 
IMAGE ID 5136328,Open Biosystems)  were amplified by PCR using the primers listed 
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in Table 4. The amplified sequences were digested with XbaI and KpnI and cloned into 
the XbaI/KpnI digested pGEM-4® vector (Promega), originating pGEM-4-Cat, pGEM-4-
AOX and pGEM-4-UOX, respectively.  
The plasmid pGEM-4-Cat was used as template to produce two other plasmids, 
one encoding a catalase lacking its last four C-terminal amino acid residues, the PTS1 
signal (CatΔKANL), and the other encoding a catalase in which these four residues 
were replaced by a glutamate and aspartate sequence (CatED). These plasmids were 
obtained using the QuickChange® Site-Directed Mutagenesis Kit (Stratagene) and the 
primer pairs described in Table 4. 
The plasmid pGEM-4-2HA-AOX was kindly provided by Dr. Marc Fransen from 
the Katholieke Universiteit of Leuven.  
A tag containing two hemaglutinin (HA) sequences (2HA-tag) was obtained by 
annealing of the following primers:  5’- AG CTT ACC ATG GGC TAC CCC TAT GAT 
GTG CCC GAT TAC GCC TAC CCA TAC GAC GTC CCA GAC TAC GCT T - 3’ and 
5’-CT AGA AGC GTA GTC TGG GAC GTC GTA TGG GTA GGC GTA ATC GGG CAC 
ATC ATA GGG GTA GCC CAT GGT A - 3’. This linker was cloned into the HindIII/XbaI 
digested pGEM-4® vector, originating the pGEM-4-2HA plasmid. The UOX cDNA was 
amplified from the commercial clone referred above using the primers listed in Table 4, 
digested with XbaI and KpnI and inserted into the previously digested pGEM-4-2HA 
vector. The final product (pGEM-4-2HA-UOX) encodes for a UOX with a 2HA-tag at its 
N-terminus. 
 
4. Synthesis of 35S-radiolabeled proteins 
 
35S-labeled proteins were synthesized using the TNT® T7 Quick Coupled 
Transcription/Translation kit (Promega) in the presence of [35S] methionine (specific 
activity >1000 Ci/mmol; PerkinElmer) following the standard conditions of the 
manufacturer. Unless otherwise indicated, protein synthesis was allowed to proceed for 
55 min and was then blocked with 0.5 mM of cycloheximide (final concentration). 
Chase incubations were performed at 30 ºC for the specified periods of time. Chase 
reactions performed in the presence of recombinant proteins typically contained 6 μl of 
the translation mixture in a final volume of 10 μl. 
 
5. Native Polyacrylamide Gel Electrophoresis 
 
Proteins were incubated in 10 μl of 50 mM Tris-HCl, pH 8.0, 2 mM DTT for 5 
min at room temperature. After addition of 1 μl of 0.17% (w/v) bromophenol blue, 50% 
(w/v) sucrose, the samples were loaded into Tris nondenaturating discontinuous 8% 
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polyacrylamide gels [165]. The gels were run at 250 V at 4 °C, for 1 hour (unless 
indicated otherwise), blotted onto nitrocellulose membranes, stained with Ponceau S 
and exposed to an x-ray film. 
 
6. Size-Exclusion Chromatography 
 
35S-labeled proteins (50 μl of in vitro transcription/translation reactions) or 
mixtures containing recombinant proteins and 35S-labeled proteins were diluted to 250 
μl with 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA-NaOH pH 8.0, 1 mM DTT 
and injected into a Superose 12 10/300 GL column (GE Healthcare; loop volume 200 
μl) running with the same buffer at 0.5 ml/min. The column was calibrated with the 
following globular proteins: ferritin (440 kDa), bovine serum albumin (66 kDa), and 
soybean trypsin inhibitor (21.5 kDa). Fractions of 500 μl were collected, subjected to 
trichloroacetic acid (TCA) precipitation, and one third of each sample was analyzed by 
SDS-PAGE. The gels were blotted onto nitrocellulose membranes, stained with 
Ponceau S and exposed to an x-ray film.  
Soluble mouse liver peroxisomal matrix proteins were obtained by sonicating 
purified peroxisomes (prepared as in Ref. [166]) in 50 mM Tris-HCl, pH 7.5, 150 mM 
NaCl, 1 mM EDTA-NaOH pH 8.0, 1 mM DTT and 1:500 (v/v) mammalian protease 
inhibitor mixture (Sigma) and centrifuging for 30 min at 100,000 x g. Two-hundred 
micrograms of soluble proteins, supplemented or not with 300 μg of recombinant 
mouse PEX5, were injected into the size-exclusion column, as above. Aliquots of 25 μl 
from each fraction were analyzed by SDS-PAGE/western blotting with antibodies 
directed to catalase (catalogue number RDICATALASEabr; Research Diagnostics, Inc) 
and L-bifunctional protein [167]. 
 
7. Sucrose Gradient Centrifugation 
 
Fifty microliters of in vitro transcription/translation reactions were incubated in 
200 μl of buffer A (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA-NaOH pH 7.4, 
1 mM DTT) for 10 min at 37 °C. Thirty micrograms of bovine immunoglobulins G (IgGs) 
(156 kDa), bovine serum albumin (BSA) (66 kDa) and chicken ovalbumin (OA) (45 
kDa) were added to the samples as internal standards. These mixtures were then 
applied onto the top of a continuous 5%-30% (w/v) sucrose gradient in buffer A. After 
centrifugation at 39,000 rpm for 29 h at 4 °C in a SW41 swing-out rotor (Beckman), 14 
fractions of 0.8 ml were collected from the bottom of the tube. One fifth of the fractions 
was subjected to trichloroacetic acid precipitation and analyzed by SDS-PAGE. The 
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gels were blotted onto nitrocellulose membranes, stained with Ponceau S and exposed 
to an x-ray film.  
 
8. Immunoprecipitations 
 
35S-labeled proteins were diluted to 500 μl with 50 mM Tris-HCl, pH 8.0, 150 
mM NaCl, 1 mM EDTA-NaOH pH 7.4, 10% (w/v) glycerol, 0.1% (w/v) Triton X-100, 
0.025% of BSA and 1:500 (v/v) mammalian protease inhibitor mixture (Sigma) and 
subjected to immunoprecipitation using 30 μl of anti-HA antibody agarose beads 
(Sigma) for 3 h at 4 ºC. Beads were washed three times with the same buffer without 
BSA and mammalian protease inhibitor mixture. The immunoprecipitated proteins were 
eluted with gel loading buffer supplemented with 100 mM DTT and subjected to SDS-
PAGE. The gels were blotted onto nitrocellulose membranes, stained with Ponceau S 
and exposed to an x-ray film. 
 
9. In vitro import reactions 
 
Rat liver post-nuclear supernatant (PNS) was prepared in buffer containing 0.25 
M sucrose, 20 mM MOPS-KOH, pH 7.4, 1 mM EDTA-NaOH, pH 7.4, 2 μg/ml N-(trans-
epoxysuccinyl)-l-leucine 4-guanidinobutylamide (E-64) (SEM buffer) as described 
before [140]. Where indicated, the reactions were supplemented with 10 ng or 50 ng of 
PEX5/PEX5N526K, 0.3 μM of TPRs/TPRsN526K or 10 μM of NDPEX14/PEX19.  
In a typical import reaction, 400 μg of rat liver PNS protein and 1 μl of a rabbit 
reticulocyte lysate containing 35S-labeled AOX or UOX were used. Incubation was for 
45 min at 37 °C in 100 μl of import buffer (0.25 M sucrose, 50 mM KCl, 20 mM MOPS-
KOH, pH 7.4, 3 mM MgCl2, 20 μM methionine, 2 μg/ml E-64, and 2 mM GSH, pH 7.2) 
containing 3 mM ATP. Recombinant proteins were added to some reactions, as 
indicated. Protease treatment of import reactions was performed on ice for 40 min 
using 400 μg/ml Proteinase K (PK) (final concentration). After inactivation of the 
protease with 500 μg/ml phenylmethylsulfonyl fluoride (PMSF) for 2 min on ice, the 
organelle suspensions were diluted to 1 ml with SEMK (SEM buffer containing 50 mM 
KCl) and isolated by centrifugation. The samples were subjected to trichloroacetic acid 
precipitation and analyzed by SDS-PAGE/Autoradiography. 
 
10. Density gradient centrifugation analysis 
 
A 4-fold scale-up of a standard import reaction was used. After PK treatment 
and inactivation of the protease, the complete import mixture was diluted to 1.5 ml with 
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SEM buffer and analyzed by Nycodenz step gradient (1.5 ml of 45% (w/v), 6 ml of 30% 
(w/v), 2 ml of 25% (w/v), and 2 ml of 20% (w/v) Nycodenz in 5 mM MOPS-KOH, pH 
7.2, and 1 mM EDTA-NaOH, pH 7.2). The tubes were centrifuged in a vertical rotor 
(STEPSAVER™ 65V13; Sorvall®) at 25,000 rpm for 2 h at 4°C. Fourteen equal 
fractions were collected from the bottom of the gradient, and a 250-μl aliquot of each 
fraction was subjected to trichloroacetic acid precipitation and SDS-PAGE. First the 
membranes were exposed to an x-ray film and then blotted with several antibodies. 
The antibodies directed to catalase (catalogue number RDI-CATALASEabr; Research 
Diagnostics, Inc.), KDEL (catalogue number ab12223; Abcam), and 
cytochrome c (catalogue number 556433; BD Pharmingen) were purchased. Rabbit 
and mouse antibodies were detected on Western blots using alkaline phosphatase-
conjugated anti-rabbit and anti-mouse antibodies (Sigma). 
 
11. Miscellaneous 
 
The concentration of PEX5 in rat liver cytosol (0.75 μM) was calculated from the 
following data: total amount of PEX5 in liver, 4 ng/μg of total peroxisomal protein; 
percentage of PEX5 in cytosol, 85% [131]; peroxisomes, 2.5% (w/w) of total liver 
protein [168]; protein content of liver, 260 mg/g [169]; one gram of liver corresponds to 
0.94 ml of which 44.4% is cytosol [170]. The weighted average molecular mass of 
monomeric rat liver peroxisomal proteins was estimated from the densitometric 
analysis of a Coomassie-stained SDS-gel loaded with a highly pure peroxisomal 
preparation [166]. Peak areas were divided by the corresponding apparent molecular 
masses and expressed as percentage of total moles. The weighted average of these 
values is 49 kDa. For newly synthesized peroxisomal proteins, this value may be 
slightly underestimated because protein maturation processes that occur in the matrix 
of the organelle (e.g., the cleavage of the 75 kDa acyl-CoA oxidase into the 53 and 22 
kDa subunits; [171]) were not taken into account. Mole percentage for catalase (13 
mole %) was calculated considering the mass percentage of the protein in rat liver 
peroxisomes, 15% [172], the weighted average molecular mass of rat liver peroxisomal 
proteins (49 kDa), the theoretical molecular mass of catalase (60 kDa), and the mass 
percentage of matrix proteins in total rat liver peroxisomes, 92% [166]. The amount of 
total peroxisomal matrix proteins in nmol/gram of rat liver was calculated from the 
above referred data. A value of 122 nmol/g of liver was obtained.  
Because “all the major protein components of the peroxisome have the same 
rate of turnover” (half-life of 1.3-1.5 days; [173, 174]) one can estimate the rate of total 
peroxisomal matrix protein synthesis (Ks) as 30 pmol/min/g of liver. The rate of 
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synthesis for a particular protein is Ks times its mole fraction in the peroxisomal matrix. 
For catalase (0.13 mole fraction) this corresponds to 3.9 pmol/min/g of liver, a value 
similar to the one reported previously (3.87 pmol/min/g of liver; [172]). The steady-state 
concentration of newly synthesized peroxisomal matrix proteins in the cytosol ([P]cyt) 
can be estimated from the expression: [P]cyt = Ks x 1.443 x t1/2, where [P]cyt is in pmol/g 
of liver and t1/2 is the cytosolic half-life of the protein in min (see [152]). According to 
Lazarow and colleagues [153, 175] several peroxisomal proteins display cytosolic half-
lives of about seven minutes (see Figure 5 in Ref. [175]). Two outliers were noted by 
those authors: one was catalase, a protein presenting a cytosolic half-life of 14 min; the 
other was urate oxidase, a protein that after 4 min of chase was already completely 
found in peroxisomes, an observation suggesting that its cytosolic half-life is 2 min or 
less. We assume that all peroxisomal matrix proteins present a similar kinetic behavior, 
i.e., that on average their cytosolic half-lives is 7-8 min. The total concentration of 
newly synthesized peroxisomal proteins in the cytosol is thus 0.73-0.83 μM, with 
monomeric catalase contributing with 0.19 μM. 
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1. Characterization of the PEX5-cargo protein interaction 
 
Presently, most of what we know regarding the interaction of PEX5 with cargo 
proteins comes from studies involving either PTS1-containing peptides or already 
folded peroxisomal matrix proteins. Although useful data have been obtained using 
these strategies, the fact remains that these studies do not reflect the in vivo situation. 
Indeed, in vivo, peroxisomal matrix proteins are synthesized in the cytosol in the 
presence of PEX5, a fact that may influence their folding/oligomerization processes 
and, therefore, their biogenesis pathway. For this reason, we decided to study the 
interaction of PEX5 with cargo proteins in a system that mimics the biological relevant 
situation. We selected catalase for our initial studies. Catalase, one of the most 
abundant peroxisomal matrix proteins, is a heme-containing enzyme containing four 60 
kDa subunits, each possessing a non-canonical PTS1 (KANL) at its C-terminus [176-
180]. The reason behind our choice is related to the controversy around the oligomeric 
state of catalase accepted by the PIM. Indeed, some authors have shown that catalase 
is imported still in its monomeric state, whereas other researchers propose that import 
occurs only after oligomerization in the cytosol [152, 153, 181-185]. 
 
1.1 – In vitro tetramerization of 35S-Catalase 
 
We started by synthesizing the radiolabeled human catalase for 90 min using 
the rabbit reticulocyte lysate-based in vitro transcription/translation system. By native-
PAGE analysis we observed three distinct populations of 35S-catalase (Figure 7A, lane 
-). Strikingly, when catalase is synthesized in the presence of 1 μM of recombinant 
PEX5, a physiological relevant concentration (see Discussion), two of these 
populations are no longer detected. Apparently, the presence of PEX5 during synthesis 
of catalase blocks some event. 
To determine the nature of the three populations, we performed a pulse-chase 
analysis where catalase was synthesized for 55 min, cycloheximide was added to 
arrest protein synthesis and the reaction was further incubated for 4 h. By native-PAGE 
analysis (Figure 7B) we observed that after 55 min of synthesis (lane 55’) the main 
product was the faster migrating population, which is converted into the slower one 
during the 4 h chase (lane 240’). The intermediary population remains constant during 
the experiment, probably representing an oligomerization intermediate, the dimeric 
form of catalase (see below). 
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To better understand the properties of each catalase population observed, we 
performed a sedimentation analysis with catalase synthesized for just 55 min or chased 
for four hours. This analysis showed that the faster migrating population corresponds to 
a specie displaying properties of a 60 kDa globular protein, whereas the slower 
migrating population behaves as a 200-250 kDa protein (data not shown). These 
findings indicate that the faster migrating catalase population represents the 
monomeric form of catalase (mCat). The 200-250 kDa species might represent either 
tetrameric catalase (tCat) or a complex between catalase and some protein(s) from the 
in vitro transcription/translation system (e.g., a chaperone).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: 35S-catalase populations after in vitro synthesis. A) Human catalase was synthesized in vitro 
in a rabbit reticulocyte lysate for 90 min at 30 ºC in the absence or presence of 1 μM human PEX5, as 
indicated, and analyzed by native-PAGE/autoradiography. B) 35S-labeled catalase was synthesized for 55 
min. After adding cycloheximide, an aliquot was removed and frozen in liquid N2 (lane 55`). The remainder 
of the reaction was then incubated at 30 ºC and aliquots were removed and frozen at the indicated time 
points. The samples were subjected to native-PAGE/autoradiography. mCat and tCat correspond to the 
monomeric and tetrameric forms of catalase; the band labeled with an asterisk probably represents 
dimeric catalase. 
 
 
To discriminate between these two possibilities, we produced an acidic mutant 
version of catalase (CatED), which migrates faster than the normal protein in native 
gels. If, in fact, the slower migrating form corresponds to the tetrameric catalase, one 
should be able to form heterotetramers with CatED, containing 1, 2 or 3 molecules of 
the normal protein; all these heterotetramers should migrate in these gels between the 
homotetramers of the parental molecules. On the other hand, if the slower migrating 
band corresponds to a complex containing catalase and some other protein(s), then 
the band pattern of the protein mixture should just correspond to the sum of the 
A B 
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patterns obtained with each of the two catalase versions individually. Both catalase and 
CatED were synthesized for 55 min (lanes 1 and 2) and then subjected to a 4 h-chase 
incubation, either individually (lanes 3 and 5) or combined (lane 4). Figure 8 shows the 
results of this experiment. Heterotetramers were indeed detected in the samples where 
the two catalase species were incubated together for 4 h. Thus, the slower migrating 
catalase species represents tetrameric catalase.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: 35S-catalase tetramerizes in vitro. Catalase and a mutant version of it possessing two acidic amino acid 
residues at the C-terminus (CatED) were synthesized in vitro for 55 min and supplemented with cycloheximide (lanes 1 
and 2, respectively). Aliquots of each reaction were then combined and incubated for 4 h at 30 ºC (lane 4) or incubated 
individually under the same conditions (lanes 3 and 5 for catalase and CatED, respectively), and subjected to native 
PAGE/autoradiography. Note that this gel was run for 2.5 hours to improve separation of tetramers. Longer 
electrophoretic runs also result in more diffuse bands. The dots in lane 4 indicate the three expected heterotetramers. 
mCatED and tCatED indicate the monomeric and tetrameric forms of CatED, respectively. 
 
 
1.2 – PEX5 binds monomeric Catalase 
 
The results presented above suggest that PEX5 interferes with catalase 
tetramerization. To better understand this phenomenon, we decided to characterize the 
interaction of PEX5 with mCat and tCat. For this purpose, we synthesized catalase for 
55 min to obtain mainly monomeric catalase and performed another reaction that was 
chased for 4 h, this one containing a mixture of monomer and tetramer. Each reaction 
was then subjected to SEC to purify mCat and tCat. The isolated proteins were 
incubated in the presence of PEX5, to allow the formation of a complex, or buffer 
alone, as a negative control, and subjected to a second SEC. 
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Figure 9: PEX5 binds monomeric 
catalase. A) 35S-labeled catalase was 
synthesized in vitro for 55 min and 
subjected to SEC. Radiolabeled mCat 
eluting in fraction 24 of this 
chromatography (panel 1; boxed lane) 
was then subjected to a second SEC 
either alone (panel 2) or after receiving 
1 μM recombinant PEX5 (panels 3 and 
4). Fractions were collected, and 
subjected to SDS-PAGE/western-
blotting. Autoradiographs (panels 1-3) 
and the Ponceau S-stained membrane 
showing PEX5 (panel 4) are 
presented. No recombinant PEX5 or 
35S-labeled catalase were detected in 
the void volume of this column 
(fractions 14-15; not shown). The 
asterisk marks bovine serum albumin 
added to chromatography fractions 
before precipitation to control protein 
recoveries. B) 35S-labeled catalase, 
synthesized in vitro for 55 min and 
incubated for 4 h at 30 ºC in the 
presence of cycloheximide, was 
subjected to SEC. Radiolabeled tCat 
eluting in fraction 20 (panel 1; boxed 
lane) was then subjected to a second 
SEC either alone (panel 2) or after 
receiving 1 μM recombinant PEX5 
(panels 3 and 4). Fractions were 
processed as described above. 
Autoradiographs (panels 1-3) and the 
Ponceau S-stained membrane (panel 
4) are presented. C) Soluble proteins 
from mouse liver peroxisomes were 
incubated either with recombinant 
PEX5 or buffer alone and subjected to 
SEC. Fractions were subjected to 
SDS-PAGE/western-blotting using 
antibodies directed to catalase 
(PerCat) or L-bifunctional protein 
(LBP). Immunoblots (panels 1-4) and 
a Ponceau S-stained membrane showing PEX5 (panel 5) are presented. Note that PEX5, a monomeric 70 kDa 
protein in solution, displays an abnormal behavior upon SEC because a major fraction of its polypeptide chain is 
natively unfolded. 
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As shown in Figure 9, mCat (fraction 24) purified by SEC behaves as a 
monomer when subjected to a second SEC (panel 2). In contrast, in the presence of 
PEX5 the elution profile of mCat changes, with the radiolabeled protein co-eluting with 
recombinant PEX5 (panels 3 and 4). Thus, PEX5 interacts with mCat.  
In Figure 9B, we present the results obtained with tCat, present in fraction 20 of 
the first SEC. In this case, the elution profiles in the presence or absence of PEX5 are 
almost identical suggesting that the interaction between these two proteins is very 
weak at best (panels 2 to 4). It is noteworthy that tCat is kept under near-equilibrium 
with recombinant PEX5 during SEC since both proteins co-elute. This should facilitate 
the formation of a complex between the two proteins. 
To extend these observations, we performed the same type of analysis with 
mouse liver peroxisomal matrix proteins (Figure 9C). After incubation with recombinant 
PEX5 or buffer alone, peroxisomal matrix proteins were subjected to SEC. The elution 
profile of mouse catalase in the presence or absence of recombinant PEX5 remains 
the same (panels 1 and 2). In contrast, the majority of L-bifunctional protein (LBP), a 78 
kDa monomeric protein in its native state, co-elutes with PEX5, showing that a complex 
between these two proteins was formed (panels 3 and 4). Taken together, our results 
strongly suggest that PEX5 binds stronger to mCat than to tCat.  
 
 
1.3 – Characterization of the PEX5-mCat interaction 
 
To better understand the PEX5-mCat interaction we performed pulse-chase 
analysis by incubating in vitro synthesized catalase with different recombinant proteins. 
As shown in Figure 10A, PEX5 at 1 μM blocks catalase tetramerization, as expected. 
Such an effect is not observed when the 4h incubation is performed in the presence of 
PEX5(N526K), a mutant PEX5 containing a single missense mutation in the PTS1-
binding domain that abolishes its activity. By titrating the PEX5 concentration 
necessary to produce an effect in catalase tetramerization, we determined that its 
inhibitory effect is quite strong, with an IC50 of about 100 nM (Figure 10B). 
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Figure 10: PEX5 inhibits catalase tetramerization. A) 35S-labeled catalase was synthesized in vitro for 
55 min (lane 55’) and chased for 4 h in the absence (lane -) or presence of 1 μM of the indicated 
recombinant proteins. B) Same as in A) but using the indicated concentrations of PEX5. Samples were 
analyzed by native-PAGE/autoradiography. 
 
Next, we asked whether the weak PTS1-signal of catalase (KANL) was 
important for PEX5-catalase interaction. Hence, we produced a mutant version of 
catalase lacking the PTS1 sequence (Cat∆KANL) and performed a pulse-chase 
analysis, in the presence or absence of 1 μM of recombinant PEX5. As shown in Figure 
11, PEX5 is no longer able to inhibit Cat∆KANL tetramerization, demonstrating that 
PEX5 inhibition of catalase tetramerization requires the PTS1 signal of catalase.  
 
 
 
 
 
 
 
 
 
 
 
Figure 11: The PTS1 of catalase is required for the interaction with PEX5. Catalase (lanes 1-3) and a 
truncated version of it lacking the PTS1 signal (catalaseΔKANL; lanes 4-6) were synthesized for 55 min, 
and chased in the absence (lanes 2 and 5) or presence of 1 μM PEX5 (lanes 3 and 6). Samples were 
analyzed by native-PAGE/autoradiography. Note that the gel was run for 2.5 hours. mCat and tCat, 
monomeric and tetrameric versions of catalase, respectively; mCatΔ and tCatΔ, monomeric and tetrameric 
forms of catalaseΔKANL, respectively. 
 
To better characterize the interaction of PEX5 with mCat we have also 
performed pulse-chase analyses using full-length PEX5 or PEX5 truncated proteins 
comprising its N-terminal half (∆C1PEX5) or its C-terminal half (TPRs) (Figure 12A). As 
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expected, in the presence of PEX5 no tetramerization is observed (lane 3). The two 
domains of PEX5 alone do not display the capacity to inhibit catalase tetramerization 
(lanes 4 and 5), not even when mixed in the same reaction at 1 μM each (lane 6). This 
last result suggests that the two domains of PEX5 have to be in the same molecule 
(i.e., they have to be in a cis configuration) to display an inhibitory effect in catalase 
tetramerization at this concentration.  
To test this hypothesis, we performed additional tetramerization assays but this 
time using 200-fold larger concentrations of TPRs and ∆C1PEX5 in the chase 
incubations. As a negative control we used PEX19, a protein involved in a different 
aspect of peroxisomal biogenesis. As shown in Figure 12B, TPRs have a strong 
inhibitory effect on catalase tetramerization at this high concentration while ∆C1PEX5 
has a weak but reproducible effect (n=5). These results show that both domains of 
PEX5 interact with mCat, an interaction that is particularly strong when the two 
domains reside in the same molecule.  
 
 
 
Figure 12: Full-length PEX5 is required to inhibit catalase tetramerization. A) 35S-labeled catalase 
was synthesized in vitro for 55 min (lane 1) and chased in the absence (lane 2) or presence of 1 μM of the 
indicated recombinant proteins (lanes 3-6). ΔC1PEX5 and TPRs, recombinant proteins comprising the N-
terminal and C-terminal half of PEX5, respectively. B) Same as in A) but using 200 μM of the indicated 
recombinant proteins. Samples were analyzed by native-PAGE/autoradiography. 
 
1.4 – The N-terminal domain of PEX14 disrupts the mCat-PEX5 interaction 
 
As referred in the Introduction section, PEX5 binds newly synthesized 
peroxisomal proteins in the cytosol, and after docking at the DTM, PEX5 then promotes 
their translocation across the membrane. Somewhere during or after this event, PEX5 
has to release the cargo protein into the organelle matrix. Previous work in yeast 
suggested that PEX8, a DTM component, might perform this task [186]. However, 
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mammals do not possess a PEX8 ortholog and therefore the triggering mechanism of 
this last event is unknown. One can assume that in mammals a DTM component could 
also be involved in this event. PEX14, an intrinsic membrane protein possessing a 
single putative transmembrane domain, would be a good candidate. PEX14 has two 
thirds of its polypeptide chain exposed to the cytosol, whereas its N-terminal third is 
either embedded in the peroxisomal membrane or exposed to the matrix of the 
organelle [187, 188]. It is also known that the N-terminal domain of PEX14 (NDPEX14) 
interacts with seven diaromatic motifs present in the N-terminal half of PEX5 [112-114]. 
Considering all of these properties, we asked if NDPEX14 affects the PEX5-
mCat interaction. In order to address this hypothesis, we used SEC to purify mCat, as 
before (Figure 13, panel 1) and incubated the radiolabeled protein with 1 μM of 
recombinant PEX5 to allow the formation of a PEX5-mCat complex. Then, the complex 
was either incubated with buffer alone or with 15 μM of NDPEX14 and subjected to a 
second SEC. As observed in Figure 13, in the presence of NDPEX14 (panels 4 and 5), 
the elution volume of PEX5 decreases indicating that a PEX5-NDPEX14 complex was 
formed. Importantly, the majority of the mCat elutes now as a monomeric protein, 
indicating that the complex between PEX5 and mCat was disrupted.  
To better understand the interaction between PEX5 and NDPEX14 and its 
effect in the PEX5-mCat interaction, we produced the following truncated versions of 
recombinant PEX5 (Figure 14): PEX5ΔN110 (amino acid residues 111-639 of PEX5), 
PEX5ΔN147 (amino acid residues 148-639 of PEX5) lacking diaromatic motifs 1 and 2, 
PEX5ΔN196 (amino acid residues 197-639 of PEX5) lacking diaromatic motifs 1 to 4, 
and PEX5ΔN267 (amino acid residues 268-639 of PEX5) and PEX5ΔN290 (amino acid 
residues 291-639 of PEX5), both lacking diaromatic motifs 1 to 6. 
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Figure 13: The N-terminal domain of PEX14 disrupts the mCat-PEX5 interaction. 35S-labeled mCat 
was purified by SEC (panel 1; fraction 24), supplemented with 1 μM recombinant PEX5 and incubated for 
30 min at room temperature to generate the PEX5-mCat protein complex. Half of this sample was 
analyzed directly by SEC (panels 2 and 3). The other half received recombinant NDPEX14 (15 μM) 30 min 
before chromatography (panels 4 and 5). Fractions were subjected to SDS-PAGE and blotted onto a 
nitrocellulose membrane. Autoradiographs (panels 1, 2 and 4) and the Ponceau S-stained membranes 
(panels 3 and 5) are presented. Hb, hemoglobin from the reticulocyte lysate that co-purified with mCat in 
the first SEC; BSA, bovine serum albumin; STI, Soybean trypsin inhibitor. 
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Figure 14: Schematic representation of recombinant PEX5 proteins. The diaromatic motifs in the N-
terminal half of PEX5 are numbered 1 to 7. Replacement of tryptophan and phenylalanine/tyrosine 
residues by alanines in these motifs is indicated by X. 
 
We first assessed the solubility of these proteins and their capacity to interact 
with NDPEX14. As shown in Figure 15, all proteins analyzed behave as single 
monodisperse species. In addition, with the exception of TPRs (a protein lacking 
diaromatic motifs) all truncated PEX5 proteins interact with NDPEX14, as expected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Native-PAGE analysis of recombinant PEX5 proteins. Native-PAGE analysis of the 
indicated PEX5 proteins (3 μg each) in the absence or presence of recombinant NDPEX14 (12 μg per 
lane). The asterisks mark the complexes between the recombinant PEX5 proteins and NDPEX14. 
Coomassie blue-stained gels are shown.   
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We then assessed the ability of these recombinant PEX5 truncated forms to 
inhibit catalase tetramerization in the absence or presence of NDPEX14 by native-
PAGE analysis. As shown in Figure 16A, PEX5ΔN110, PEX5ΔN147 and PEX5ΔN196 
have a similar effect in catalase tetramerization as the full-length protein. In the 
presence of NDPEX14 this effect was abolished, in a similar way to what has been 
already observed when using PEX5. PEX5ΔN267, has a partial inhibitory effect in 
catalase tetramerization but in the presence of NDPEX14 this effect was also 
abolished. Finally, PEX5ΔN290 has no effect in catalase tetramerization. Taken 
together these results show that the smallest molecule of PEX5 that still retains the 
capacity to inhibit catalase tetramerization at low concentration (1 μM) is PEX5ΔN196 
and that the region between amino acids 197 and 290 of PEX5 is important in the 
mCat-PEX5 interaction. In addition, binding of NDPEX14 to PEX5ΔN267 is sufficient to 
disrupt its interaction with mCat, suggesting that the single diaromatic motif (7th) 
present in PEX5ΔN267 is important to this interaction. 
Knowing this, we produced another version of recombinant PEX5 where we 
mutated the only diaromatic motif present in PEX5ΔN267. The tryptophan and tyrosine 
residues were replaced by alanines, to block the binding of NPEX14 [113], resulting in 
PEX5ΔN267-M7 (Figure 14). Using the same approach to address catalase 
tetramerization, one observed that this protein no longer inhibits catalase 
tetramerization (Figure 16B). We assumed that these mutations may have caused 
some structural/conformational alterations in PEX5. So, we produced a full-length 
version of PEX5 possessing the same mutation, PEX5-M7 (Figure 14), and tested it in 
the same assay. Interestingly, as shown in Figure 16C, PEX5-M7 has the same 
inhibitory effect in catalase tetramerization as PEX5, an effect which is also neutralized 
by NDPEX14. These results suggest that other regions of PEX5 might compensate for 
the absence of the 7th diaromatic motif and that at least one of the remaining 6 
diaromatic motifs present in PEX5-M7 is involved in the NDPEX14-induced disruption 
of the mCat-PEX5 interaction. 
To identify additional diaromatic motifs involved in the NDPEX14-induced 
inactivation of PEX5 we produced a full-length version of PEX5 mutated in both the 6th 
and the 7th diaromatic motifs, PEX5-M6,7 (Figure 14). Using the same approach, we 
observed that PEX5-M6,7 has a less potent inhibitory effect in catalase tetramerization 
comparing to PEX5 (Figure 16C). Moreover, NDPEX14 is no longer capable of 
disrupting the mCat-PEX5-M6,7 interaction. These results suggest that binding of 
NDPEX14 to the 6th (and probably the 7th) diaromatic motif of PEX5 disrupts mCat-
PEX5 interaction. 
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Figure 16: PEX5 diaromatic motifs involved in the NDPEX14-induced disruption of the mCat-PEX5 
interaction. A-C) 35S-labeled catalase was synthesized in vitro for 55 min (lane 55’) and chased for 4 h in 
the absence (lane -) or presence of 1 μM of the indicated recombinant PEX5 proteins alone or together 
with NDPEX14 (30 μM). Samples were analyzed by native-PAGE/autoradiography. 
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2. The interaction of monomeric/oligomeric proteins with the PIM 
 
The data presented in the previous section revealed that PEX5 interacts 
strongly with monomeric catalase, blocking its tetramerization. Because the amount of 
cytosolic PEX5 in a cell is probably sufficient to bind mCat and all the other newly 
synthesized proteins that are en route to the organelle (see Discussion), those results 
raised the interesting possibility that monomeric proteins are the preferred substrate for 
the PIM, at least at the PEX5 level. Obviously, it could also be that the data on the 
PEX5-catalase interaction reflects some particularity of this cargo protein and not a 
general property of peroxisomal matrix proteins. Thus, we decided to characterize the 
interaction of PEX5 with other cargo proteins. We selected for this task peroxisomal 
matrix proteins having canonical PTS1 sequences which bind to PEX5 in a much 
stronger manner than the KANL sequence of catalase [189]. We reasoned that with 
these cargo proteins we might be able to characterize their import into the organelle. 
Such an assumption turned out to be correct as described below. 
 
2.1 – 35S-AOX dimerizes in vitro and its dimerization is inhibited by PEX5 
 
We first focused our attention in Acyl-CoA oxidase 1 (here after referred to as 
AOX). AOX is a homodimeric protein in its native state (2 x 72 kDa) with a canonical 
PTS1 (SKL) at its C-terminal [190, 191].  
To determine if dimerization of 35S-AOX occurs in vitro and whether this event 
can be inhibited by PEX5, we synthesized AOX for 30 min, added cycloheximide to 
stop further protein synthesis, collected a sample and performed a 4 h chase in the 
presence or absence of 1 μM recombinant PEX5. Due to its alkaline isoelectric point, 
AOX cannot be analyzed by native-PAGE as catalase. Therefore, AOX samples were 
analyzed by centrifugation in sucrose gradients.  
Four gradients were analyzed: two having a control protein along the gradient to 
analyze the oligomeric state of AOX (30 min and 4 h chase, in the absence of PEX5, 
panel 1 and 2); and the other two having 1 μM recombinant PEX5 along the gradient to 
compare the profile of the 4 h-chased AOX in the presence and absence of PEX5 and 
simultaneously its interaction with the recombinant protein (panel 3 and 4). As shown in 
Figure 17, after 30 min of synthesis (panel 1) the AOX population observed displays 
the behaviour of a 70 kDa globular protein, thus suggesting that AOX is in a monomeric 
state (mAOX). After a 4 h chase, in the absence of PEX5, we detected a population 
behaving as a 150 kDa protein (lane 9, panel 2), probably representing the dimeric 
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form of AOX (dAOX). When the samples were analyzed in a gradient containing 
recombinant PEX5, we observed that both mAOX and dAOX were shifted towards the 
bottom of the gradient (panel 3), suggesting that both mAOX and dAOX interact with 
PEX5. When the 4 h chase is performed in the presence of 1 μM PEX5 (panel 4), the 
dAOX population is no longer observed, suggesting that PEX5 inhibits AOX 
dimerization as observed before for catalase. 
Figure 17: Sucrose gradient sedimentation analysis of 35S-AOX populations. A 30 min reaction and a 
4h-chase in the presence or absence of 1 μM of recombinant PEX5 were loaded onto the top of sucrose 
gradients, supplemented either with a control protein or PEX5. After centrifugation, the fractions were 
collected from the bottom of the tube, subjected to SDS-PAGE and blotted onto nitrocellulose membranes. 
Autoradiographs are shown. BSA, bovine serum albumin; OA, ovalbumin; IgGs, immunoglobulins G. 
 
To determine if the second population observed in the sucrose gradients indeed 
corresponds to dAOX, two different strategies were used. In the first, we used protease 
assays to monitor the proteolytic profiles of mAOX and dAOX. We performed a titration 
of PK and also a time-course analysis. As shown in Figure 18A, 35S-mAOX is highly 
susceptible to PK digestion, even at low concentration of the protease. In contrast, 35S-
dAOX has an intrinsic resistance (fragment of 51 kDa) (arrow) to PK digestion even at 
high concentrations of the protease. Also, when using the maximum concentration of 
PK (400 μg/ml), mAOX is completely digested just after 5 min of incubation, while 
dAOX remains resistant even after 40 min of digestion (Figure 18B). 
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Figure 18: dAOX is intrinsically resistant to protease treatment. A)  mAOX and dAOX were isolated 
from a sucrose gradient, incubated with different concentrations of PK for 40 min. B)  mAOX and dAOX 
were isolated from a sucrose gradient, incubated with 400 μg of PK and different aliquots were removed at 
the indicated time points. After protease inactivation, all samples were subjected to trichloroacetic acid 
precipitation and analyzed by SDS-PAGE. Autoradiographs are shown. Numbers on the left indicate the 
standard molecular weights; i, 5% input. 
 
We performed the same analysis comparing the behaviour of 35S-dAOX with 
that of native AOX from mouse liver peroxisomes. We performed a PK treatment of 
purified mouse liver peroxisomes in the presence of Triton X-100 to solubilize the 
peroxisomal membrane. All samples were analyzed by SDS-PAGE and the 
membranes were blotted with antibodies against the 51 kDa and the 21 kDa fragments 
of AOX. As shown in Figure 19, 35S-dAOX displays the same proteolytic profile as the 
native AOX, as assessed using the antibody against the 51 kDa fragment. The 53 kDa 
fragment is originated after AOX processing inside the peroxisome, and thus is not 
present in 35S-dAOX, while the 51 kDa fragment is originated after PK treatment and is 
the result of intrinsic resistance of the AOX dimer to the protease. 
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Figure 19: 35S-dAOX behaves as native AOX in protease treatment. 35S-dAOX and native AOX (from 
purified mouse liver peroxisomes) were subjected to protease treatment in the presence of Triton X-100. 
Following PK inactivation, the samples were subjected to trichloroacetic acid precipitation and analyzed by 
SDS-PAGE. For dAOX the autoradiograph is shown and for native AOX immunoblotting against the 51 
kDa and 21 kDa fragments of AOX is shown. Numbers on the left indicate the standard molecular weights; 
F, front of the gel. 
 
Western-blot analisys using the anti-21 kDa fragment antibody, reveals that this 
domain of native AOX is protease resistant. We were able to detect a similar fragment 
in the PK-treated 35S-dAOX (arrow head in left panel). The low intensity of this 
fragment in the autoradiograph can be explained by the fact that only one of the 18 
methionines present in AOX is present in this domain of the protein. The finding that 
35S-dAOX (but not 35S-mAOX) behaves as native AOX from mouse liver upon protease 
treatment suggests that the two proteins have similar structures. 
In the second strategy, we produced a tagged version of AOX with a 2HA-tag 
added to its N-terminus (HA-AOX). Then, both HA-AOX and AOX were synthesized 
individually or together in the presence or absence of 1 μM recombinant PEX5. After 
the addition of cycloheximide, all samples were subjected to a 4 h chase to allow 
dimerization to occur. In this experimental setting, if AOX is indeed able to dimerize in 
vitro, one should be able to detect heterodimers comprising HA-AOX and the untagged 
AOX. As shown in Figure 20, when an immunoprecipitation using an anti-HA antibody 
was performed using a mixture of the individual proteins, no AOX was co-
immunoprecipitated with HA-AOX. However, when proteins are co-synthesized in the 
absence of PEX5, a fraction of AOX was co-immunoprecipitated with HA-AOX. In 
agreement with the results obtained for catalase, when the co-synthesis of HA-AOX 
and AOX is performed in the presence of PEX5 no oligomerization was detected.  
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Taken together these findings suggest that PEX5 interacts with mAOX, blocking 
its dimerization. 
Figure 20: 35S-AOX dimerizes in vitro. AOX and HA-AOX were synthesized individually (lanes 1 and 2) 
and co-translationally in the absence or presence of 1μM of recombinant PEX5 (lanes 4 and 5, 
respectively) and subjected to a 4 h-chase. A mixture of the two proteins synthesized individually can be 
observed in lane 3. The samples (lanes 3 to 5) were subjected to immunoprecipitation using an anti-HA 
antibody agarose beads. The immunoprecipitated proteins (lanes 6 to 8) were washed, eluted from the 
beads and analyzed by SDS-PAGE. Autoradiograph is shown. -, no PEX5 during synthesis; +, 1 μM PEX5 
during synthesis; (+), addition of equivalent amount of PEX5 before the immunoprecipitation. 
 
2.2 – mAOX is a better substrate than dAOX for the peroxisomal matrix 
protein import machinery 
 
As shown above, we were able to develop a procedure to obtain purified 35S-
mAOX and 35S-dAOX. The availability of these two forms of AOX gave us the 
opportunity to compare the import efficiencies of a cargo protein in its monomeric and 
oligomeric state. Obviously, we first determined whether or not we could import 35S-
AOX using an in vitro import system.  We performed an in vitro import reaction using a 
rabbit reticulocyte system containing both mAOX and dAOX. The import reaction was 
performed in the presence of PEX5 and/or other recombinant proteins: PEX5(N526K), 
NDPEX14, and PEX19 (1-124), a truncated version of PEX19, a protein involved in 
other aspect of peroxisome biogenesis. As shown in Figure 21, 35S-AOX import is 
increased in the presence of recombinant PEX5 and, as expected, not in the presence 
of recombinant PEX5(N526K). When NDPEX14 is added to the reaction there is a 
significant decrease in the levels of imported AOX. This indicates that NDPEX14 
interacts with both endogenous and recombinant PEX5, thus blocking AOX import. 
Noteworthy, these results show the clear difference between the 53 kDa fragment that 
is originated from processing of mAOX after import into the organelle (upper arrow)  
and the 51 kDa fragment that is originated from the intrinsic resistance of dAOX to PK 
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(lower arrow). The latter is present in all lanes with the same intensity, independently of 
import conditions, while the 53 kDa fragment is specific of mAOX import and presents a 
similar behaviour as the full-length AOX.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Specificity of the AOX import into the peroxisomes. A rat liver PNS fraction was incubated 
with a 35S-labeled mixture of mAOX and dAOX in import buffer containing ATP in the absence (lane 2) or 
presence of recombinant PEX5 (lane 3), PEX5(N526K) (lane 4), NDPEX14 (lane 5), PEX5 and NDPEX14 
(lane 6) and PEX19(1-124) (lane 7). After PK treatment, the organelles were isolated by centrifugation, 
subjected to SDS-PAGE, and blotted onto a nitrocellulose membrane. The Ponceau S-stained membrane 
(lower panel) and its autoradiograph (upper panel) are shown. Numbers on the left indicate the standard 
molecular weights. 
 
After confirming that 35S-AOX can be imported using an in vitro import system, 
we performed import reactions using either the mAOX or the dAOX isolated from 
sucrose gradients. All reactions were performed in the presence of 10 ng of 
recombinant PEX5, as we found that this amount of PEX5 increases the import yield of 
AOX by a factor of two (Figure 21, lane 3). Two other recombinant proteins were also 
used in import assays to assess the specificity of these import reactions. These were 
TPRs to compete with PEX5 for cargo binding and so to inhibit the import reaction 
[109] and TPRs(N526K), mutant version of TPRs unable to bind to the PTS1 signal, as 
a control. Following import, the reactions were divided into two halves. One was 
subjected to PK treatment whereas the other was left untreated. As shown in Figure 
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22, in the absence of PK treatment there is no significant difference between the 3 
conditions (PEX5, TPRs and TPRsN526K) and between mAOX and dAOX. This is not 
the case after PK treatment. In the presence of PEX5 we observed that a reasonable 
amount of mAOX was imported (it is resistant to PK treatment) and that this import is 
specific since it was inhibited by TPRs and not by TPRs(N526K) (lanes 5 and 6). The 
same was not observed for dAOX. In this case, we found that most radiolabeled AOX 
found in organelle pellets (lanes 7-9) was not protected from PK, indicating that most 
dAOX sedimenting with organelles is simply adsorbed at their surface. Furthermore, 
although a small fraction of dAOX resisted to PK treatment (lanes 10-12), most of this 
protease-resistant material was insensitive to the presence of TPRs in the reaction. 
Thus, we are not sure that this protease-resistant species really represents imported 
protein. 
 
Figure 22: mAOX and dAOX import into peroxisomes. A rat liver PNS fraction was incubated either 
with 35S-labeled mAOX or dAOX in import buffer containing ATP, in the presence of recombinant PEX5, 
TPRs or TPRs(N526K). After PK treatment, the organelles were isolated by centrifugation, subjected to 
SDS-PAGE, and blotted onto a nitrocellulose membrane. The Ponceau S-stained membrane (lower panel) 
and its autoradiograph (upper panel) are shown. Numbers on the left indicate the standard molecular 
weights; i, 5% input. 
 
In order to understand if the mAOX is being specifically imported into the 
peroxisomal compartment, we subjected import reactions programmed with 35S-mAOX 
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and 35S-dAOX to Nycodenz gradient centrifugation. The gradients were then 
fractionated and equal volumes of each fraction were analyzed by SDS-PAGE. As 
shown in Figure 23, catalase, a peroxisomal matrix protein displays a dual behaviour. 
One fraction is recovered in fractions 2 and 3 (bottom) of the gradient and represents a 
population of highly pure peroxisomes, and the other peaks at fractions 11 to 14 
representing protein that leaked from peroxisomes during PNS 
preparation/manipulation. In the gradient were mAOX was analyzed, the full-length 
AOX has a distribution profile similar to catalase, indicating that 35S-AOX was 
specifically imported into the peroxisomes. Regarding the gradient containing dAOX, 
we can observe that the majority of the protein was not imported into peroxisomes, 
being distributed through the top half of the gradient in the form of the 51 kDa fragment 
resistant to the PK treatment. Taken together these results strongly suggest that mAOX 
is a better substrate for the peroxisomal import machinery than dAOX. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: 35S-mAOX is specifically imported into peroxisomes. A PEX5-supplemented PNS fraction was incubated 
with 35S-labeled AOX in import buffer containing ATP for 45 min. After PK treatment and inactivation of the protease, the 
complete import mixture was diluted with SEM buffer and subjected to Nycodenz gradient centrifugation. The gradient 
was then fractionated from the bottom (lane 1) to the top (lane 14), and equal aliquots from each fraction were subjected 
to SDS-PAGE and Western blotting. The nitrocellulose membrane was exposed to an x-ray film to detect the 35S-labeled 
protein (x-ray panels) and afterward probed with the following antisera: anti-KDEL (KDEL; recognizes GRP72 and 
GRP98, two endoplasmic reticulum proteins), anti-cytochrome c (Cyt c; a mitochondrial marker) and anti-catalase (CAT; 
a peroxisomal enzyme). Note that catalase remaining at the top of the gradient results from leakage of 
peroxisomes. Numbers on the left indicate the standard molecular weights. 
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2.3 – PEX5 inhibits UOX tetramerization and mUOX is the preferred 
substrate for the PIM 
 
We decided to extend our work to another abundant protein of the peroxisomal 
matrix: urate oxidase (hereafter referred to as UOX). UOX is a protein with four 34 kDa 
subunits with a canonical PTS1 (SRL) at their C-terminus [7, 10]. We started by 
synthesizing radiolabeled UOX for 45 min, using the rabbit reticulocyte lysate-based in 
vitro transcription-translation system. After synthesis arrest with cycloheximide, a 
sample was collected and a 4 h chase was performed. Like AOX, UOX has an alkaline 
isoelectric point and cannot be analyzed by native-PAGE. The samples were analyzed 
by centrifugation in sucrose gradients. As shown in Figure 24, after 45 min of synthesis 
the population observed behaves as a 35 kDa globular protein, suggesting that UOX is 
in a monomeric state (mUOX). After a 4 h chase, a second population is observed and 
it behaves as a 150 kDa protein, being probably the tetrameric form of UOX (tUOX). 
 
 
 
 
 
 
 
 
Figure 24: Sucrose gradient sedimentation analysis of 35S-UOX populations. A 45 min reaction and a 
4 h-chase in the absence of any recombinant protein were loaded onto the top of sucrose gradients. After 
centrifugation, the fractions were collected from the bottom of the tube, subjected to SDS-PAGE and 
blotted onto nitrocellulose membranes. Autoradiographs are shown. BSA, bovine serum albumin; OA, 
ovalbumin; IgGs, immunoglobulins G. 
 
To determine if the second population observed in the sucrose gradients 
corresponds to tUOX, we monitored the proteolytic profile of mUOX and tUOX by 
performing protease assays. Both mUOX and tUOX were isolated from sucrose 
gradients and incubated with 400 μg of PK. Aliquots were collected at different time 
points and analyzed by SDS-PAGE. As shown in Figure 25, mUOX is completely 
susceptible to protease treatment while tUOX is mainly resistant to proteolysis yielding 
a diffuse double band, displaying an apparent molecular mass almost identical to the 
one of the intact UOX. 
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Figure 25: tUOX is resistant to protease treatment. mUOX and tUOX were isolated from a sucrose 
density gradient centrifugation, incubated with 400 μg of PK and different aliquots were withdrawn at the 
indicated time points. After inactivation of the protease, all samples were subjected to trichloroacetic acid 
precipitation and analyzed by SDS-PAGE. Autoradiographs are shown. Numbers on the left indicate the 
standard molecular weights. 
 
Next, we produced a tagged version of UOX, with a 2HA-tag added to the N-
terminal (HA-UOX). We synthesized both untagged UOX and HA-UOX individually or 
together in the presence or absence of 1 μM recombinant PEX5. After synthesis arrest 
with cycloheximide, a 4 h chase was performed to allow oligomerization to occur. As 
described for AOX, we performed an immunoprecipitation using an anti-HA antibody. 
As shown in Figure 26, when the immunoprecipitation was performed with a mixture of 
the individual proteins, no UOX was co-precipitated with HA-UOX. Oligomers were 
detected only when both UOX and HA-UOX were co-synthesized in the absence of 
PEX5. In the presence of PEX5, UOX oligomerization was no longer detected.  
 
Figure 26: 35S-UOX tetramerizes in vitro. UOX and HA-UOX were synthesized individually (lanes 1 and 
2) and in a co-translation reaction in the absence or presence of 1μM of recombinant PEX5 (lanes 4 and 5, 
respectively) and subjected to a 4 h chase. A mixture of the two proteins synthesized individually can be 
observed in lane 3. The samples (lanes 3 to 5) were subjected to immunoprecipitation using an anti-HA 
antibody agarose beads. The immunoprecipitated proteins (lanes 6 to 8) were washed, eluted from the 
beads and analyzed by SDS-PAGE. Autoradiograph is shown. -, no PEX5 during synthesis; +, 1 μM PEX5 
during synthesis; (+), addition of equivalent amount of PEX5 before the immunoprecipitation. 
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Having both mUOX and tUOX isolated from sucrose gradients, we were able to 
compare the import efficiencies of these proteins by performing in vitro import 
reactions. All reactions were performed in the presence of 50 ng of PEX5 to increase 
import yield. As described for AOX, TPRs and TPRs(N526K) were added to the 
reactions when needed. Following import, the reactions were divided into two halves. 
One was subjected to PK treatment whereas the other was left untreated. As shown in 
Figure 27, in the absence of PK treatment there is no significant difference between the 
3 conditions (PEX5, TPRs and TPRsN526K) and between mUOX and tUOX. After PK 
treatment, in the presence of PEX5 we observed a small amount of mUOX that 
presents PK resistance, indicating that it is was imported (lane 4). This import is 
specific since it was inhibit by TPRs and not by TPRs(N526K) (lanes 5 and 6). For 
tUOX the same result was not observed. Taken together these results show that, like 
AOX, PEX5-UOX interaction inhibits its tetramerization and that mUOX is the preferred 
substrate for the matrix protein import machinery.  
 
Figure 27: mUOX and tUOX import into peroxisomes. A rat liver PNS fraction was incubated with 35S-
labeled mUOX or tUOX, individually, in import buffer containing ATP, in the presence of recombinant 
PEX5, TPRs or TPRs(N526K). After PK treatment, the organelles were isolated by centrifugation, 
subjected to SDS-PAGE, and blotted onto a nitrocellulose membrane. The Ponceau S-stained membrane 
(lower panel) and its autoradiograph (upper panel) are shown. Numbers on the left indicate the standard 
molecular weights; i, 5% input. 
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In this work we used an in vitro approach to characterize the PEX5-cargo 
protein interaction. As previously mentioned, whether PEX5 binds to monomeric or 
oligomeric versions of the matrix proteins was still a controversial subject. Our results 
show that, at least for three very abundant peroxisomal matrix proteins (cat, AOX and 
UOX), PEX5 binding to the monomeric version of these proteins inhibits their 
oligomerization. This PEX5 characteristic was best addressed using catalase. The 
proposed mechanism for the catalase assembly pathway consists of three steps: 1) 
apo-monomers + heme → holomonomers; 2) holomonomers → holodimers; 3) 
holodimers → holotetramers (reviewed in [192]). Our results suggest that in the 
presence of PEX5 step 2 no longer occurs. 
When evaluating the affinity of PEX5 for both mCat and tCat, we found that the 
PEX5-mCat interaction is favored. In this work we show that not only the C-terminal but 
also the N-terminal half of PEX5 has a role in PEX5-mCat interaction, specially since 
the inhibitory effect in catalase tetramerization is increased when both domains are in 
the same molecule. In the literature, we can find several data suggesting that the 
interaction of the N-terminal half of PEX5 with catalase is also observed in other 
organisms. In yeast, Kragler and co-workers showed that catalase possesses not only 
the PTS signal at its C-terminal but also another peroxisomal targeting information at 
its N-terminal [120]. In plants, it was observed that the last four residues of cottonseed 
catalase are sufficient to target a reporter protein to the peroxisome [193]. These 
residues are conserved in pumpkin catalase. However, this protein was also shown to 
interact with the N-terminal half of PEX5 [121]. Taken together, the results suggest that 
PEX5 possesses more than one catalase-interacting domain. 
In order to corroborate these observations, we also addressed this issue using 
two other major matrix proteins, AOX and UOX. Our results show that PEX5 also 
inhibits their oligomerization. This PEX5 property is only relevant if the amount of 
cytosolic PEX5 in a cell is enough to sequester all newly synthesized peroxisomal 
proteins en route to the organelle. We estimated that the cytosolic concentration of 
PEX5 in rat hepatocytes is 0.75 μM and that the concentration of newly synthesized 
peroxisomal proteins is in a range of 0.73 – 0.83 μM (see Miscelaneous in 
“Experimental Procedures”). Taken together our experimental results and these 
estimated values, we proposed that PEX5 binds peroxisomal matrix proteins 
immediately after their synthesis keeping them in a monomeric state.  
Next, we evaluated which was the best substrate to the matrix protein import 
machinery. The work performed with AOX and UOX suggests that the monomer is the 
preferred substrate for the PIM. The results presented here thus corroborate and 
extend the observations of Lazarow and de Duve [152, 153]. Indeed, using pulse-
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chase analysis, these authors were able to show that the major pathway for catalase 
import involved the translocation of monomeric catalase across the peroxisomal 
membrane. Two other studies suggest that the monomeric version of a given protein is 
imported into the organelle: malate synthase in cucumber glyoxysomes [154] and 
alcohol oxidase in the methylotrophic yeast Candida boidinii [155]. 
Many studies have shown that peroxisomes can import already oligomerized 
proteins. However, those studies were conducted under protein over-expression 
conditions, frequently using very strong promoters to drive expression of the protein 
being analyzed [158, 161, 184, 194]. It is therefore possible that the observed import of 
oligomerized proteins is the result of an artificial situation in which PEX5 or other 
components of the PIM become stoichiometrically limiting. Despite these limitations, 
many authors proposed that only already folded proteins can be imported into the 
organelle [185]. According to those authors, the “proff-of-concept” for this model comes 
from the work of Danpure and co-workers on alanine-glyoxylate aminotransferase 
(AGT) [195, 196]. Indeed, it was proposed that AGT has to dimerize in the cytosol 
before import. The data behind this idea comes from the observation that mutations 
that affect dimerization of AGT result in the degradation or mistargeting of the protein, 
leading to the mistargeting of the protein to the mitochondria. This results in the 
hereditary kidney-stone disease primary hyperoxaluria type 1. Unfortunately, those 
authors never considered the possibility that mutations affecting the dimerization of 
AGT may also affect the structure of monomeric AGT, and thus, the interactions of 
these mutant proteins with cytosolic chaperones and PEX5 itself.   
Another caveat of the studies mentioned above regards import kinetics of 
oligomerized cargo proteins. In fact, only the work performed with chloramphenicol 
acetyltransferase (CAT) by Goodman and co-workers addressed this important 
question [159]. In that work, the import of trimeric CAT, measured by immunoelectron 
microscopy and organellar fractionation, was shown to occur over several hours, in 
contrast with the import of other peroxisomal proteins [152, 153, 155]. In our work, we 
compare the import efficiency of monomeric and oligomeric versions of two 
peroxisomal matrix proteins. Even though we cannot exclude that peroxisomes can 
import already folded proteins, our results strongly suggest that the monomers are the 
preferred substrate for the peroxisomal import machinery. 
The strong binding of PEX5 to the monomeric version of peroxisomal matrix 
proteins, inhibiting their oligomerization, resembles the properties of a chaperone 
protein. In this regard, it is interesting to note that this capacity of PEX5 of inhibiting 
cargo proteins oligomerization evokes the properties of a family of bacterial 
chaperones functioning in type III secretion systems. The type III secretion pathway is 
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used by several pathogenic bacteria to deliver proteins to the eukaryotic cells with 
which they interact. The proteins that will be secreted are synthesized in the cytosol, 
where they have to be stabilized and separated from other interaction partners to be 
kept in a secretion-competent state. Chaperones, without any energetic requirement, 
have an important role by associating in the cytosol with these proteins before their 
secretion. There are several types of chaperones in this secretion system, some them 
possessing TPR motifs ([197, 198] and reviewed in [199]). The interaction between 
these chaperones and the proteins is crucial for the secretion itself since it prevents 
premature or incorrect interactions. A parallelism can thus be established with PEX5 
and peroxisomal matrix proteins, i.e., PEX5 prevents the interaction between the 
monomers of a given protein until they reach the matrix of the organelle.  
PEX14, a central component of the DTM, was seen for many years as a protein 
involved only in the docking of the receptor at the peroxisomal membrane [19]. 
However, several observations showed that this protein also has a role in the 
translocation of cargo proteins across the membrane of the organelle [139, 200]. Our 
results show that the N-terminal domain of human PEX14 disrupts the PEX5-mCat 
interaction. Data reported earlier for Leishmania donovani PEX5 showed that its affinity 
for a PTS1 protein is decreased in the presence of PEX14 [201]. Taken together, these 
results suggest another function for this membrane protein, a role in the release of 
cargoes from DTM-embedded PEX5 into the peroxisomal matrix (Figure 28).  
From the seven diaromatic motifs present in human PEX5, only one or two have 
a major role in the NDPEX14-induced disruption of the mCat-PEX5 interaction. 
Previous data showed that diaromatic motifs 2–4 of PEX5 are required for catalase 
import in vivo [112]. Taken together, these results suggest that several interactions are 
occurring in a sequential manner between the N-terminal domain of peroxisomal 
PEX14 and the diaromatic motifs present in PEX5 and may serve two different 
purposes. According to this hypothetical model, the first set of interactions may 
contribute to the docking/insertion of the PEX5-cargo protein complex into the DTM; 
subsequently, binding of additional PEX14 molecules to the 6th (and probably 7th) 
diaromatic motif(s) of PEX5 would trigger the release of the cargo protein into the 
peroxisomal matrix. 
 
 
 
 
 
 
V. DISCUSSION 
55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: Role of PEX14 in the release of cargo proteins into the peroxisomal matrix. A newly 
synthesized cargo protein (CP) is recognized by PEX5 in the cytosol. This protein complex then docks at, 
and becomes inserted into the peroxisomal DTM of which only PEX14 is shown for simplicity. The DTM 
component(s) providing the docking site for the PEX5-cargo protein complex have not been 
unambiguously identified yet. As discussed elsewhere, two strong candidates for this role are PEX13 [138] 
and PEX14 itself [202, 203]. Note that PEX13 may also participate in the cargo-release step [112]. The 
multiple interactions of PEX5 with the N-terminal domain of the several PEX14 molecules present in the 
DTM ultimately trigger the release of the cargo into the peroxisomal matrix. 
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In this work we have demonstrated that: 
 
- PEX5 interacts with the monomeric version of three matrix proteins (Cat, AOX 
and UOX) and inhibits their oligomerization; 
 
- The N-terminal of PEX5 has a role in cargo-binding; 
 
- NDPEX14 disrupts the mCat-PEX5 interaction, through the binding to the 6th 
(and probably the 7th) diaromatic motif of PEX5; 
 
- mAOX and mUOX are the preferred substrates for the peroxisomal import 
machinery. 
 
 
Numerous data have been gathered concerning the matrix protein import 
pathway.  This work provides new insights into this pathway by showing a new property 
of PEX5. This chaperone characteristic defines an important new role to the cytosolic 
receptor.  
 
Even more, this work elucidated the controversial subject of monomeric or 
oligomeric import, since it showed that even though oligomers might be imported, the 
monomers are the preferred substrate for the import machinery. 
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PEX5 Protein Binds Monomeric Catalase Blocking Its
Tetramerization and Releases It upon Binding the N-terminal
Domain of PEX14*□S
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Background: PEX5 binds newly synthesized peroxisomal proteins in the cytosol and releases them in the organelle matrix.
Results: PEX5 binds monomeric catalase and releases it in the presence of PEX14.
Conclusion: PEX14 participates in the cargo release step.
Significance: Knowing how PEX5 interacts with cargo proteins and which factors disrupt this interaction are crucial for
understanding this protein sorting pathway.
Newly synthesized peroxisomal matrix proteins are targeted
to the organelle by PEX5. PEX5 has a dual role in this process.
First, it acts as a soluble receptor recognizing these proteins in
the cytosol. Subsequently, at the peroxisomal docking/translo-
cationmachinery, PEX5promotes their translocation across the
organelle membrane. Despite significant advances made in
recent years, several aspects of this pathway remain unclear.
Two important ones regard the formation and disruption of the
PEX5-cargo protein interaction in the cytosol and at the dock-
ing/translocation machinery, respectively. Here, we provide
data on the interaction of PEX5with catalase, a homotetrameric
enzyme in its native state. We found that PEX5 interacts with
monomeric catalase yielding a stable protein complex; no such
complexwas detectedwith tetrameric catalase. Binding of PEX5
to monomeric catalase potently inhibits its tetramerization, a
property that depends on domains present in both the N- and
C-terminal halves of PEX5. Interestingly, the PEX5-catalase
interaction is disrupted by the N-terminal domain of PEX14, a
component of the docking/translocationmachinery.One or two
of the seven PEX14-binding diaromatic motifs present in the
N-terminal half of PEX5 are probably involved in this phenom-
enon. These results suggest the following: 1) catalase domain(s)
involved in the interaction with PEX5 are no longer accessible
upon tetramerization of the enzyme; 2) the catalase-binding
interface in PEX5 is not restricted to its C-terminal peroxisomal
targeting sequence type 1-binding domain and also involves
PEX5 N-terminal domain(s); and 3) PEX14 participates in the
cargo protein release step.
Mammalian peroxisomal matrix proteins are synthesized on
cytosolic ribosomes and post-translationally targeted to the
organelle matrix by PEX5, the peroxisomal shuttle receptor
(1–4). The vast majority of these proteins possess the so-called
peroxisomal targeting signal type 1 (PTS1),4 a C-terminal
sequence frequently ending with the tripeptide SKL or a deriv-
ative of it (5). This PTS1 interacts directly with the C-terminal
half of PEX5, a domain comprising seven tetratricopeptide
repeats motifs arranged into a ring-like structure (6). A minor
fraction of peroxisomal matrix proteins contains instead a PTS
type 2 (PTS2), a degenerated nonapeptide near their N termini
(7). The PTS2-PEX5 interaction is not direct but rather ismedi-
ated by the adaptor protein PEX7 (8).
According to current models (1–4), newly synthesized per-
oxisomal matrix proteins interact with PEX5 while still in the
cytosol. These PEX5-cargo protein complexes then dock at the
peroxisomal docking/translocation machinery (DTM), a mul-
tisubunit protein complex comprising the intrinsic membrane
proteins PEX13, PEX14, and the RING finger peroxins PEX2,
PEX10, and PEX12 (9, 10). By a still ill-defined process, this
interaction ultimately leads to the insertion of PEX5 into the
DTM with the concomitant translocation of the cargo protein
into the peroxisomalmatrix (11–13). In at least one case, that of
the PTS2-containing protein thiolase, it is also at this stage that
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PEX5 releases its cargo into the peroxisomal matrix (11). Inter-
estingly, in vitro import experiments suggest that ATP hydro-
lysis is not needed at any of these steps, suggesting that the
complete transport of a cargo protein from the cytosol into the
peroxisomal matrix is driven by thermodynamically favored
protein-protein interactions at the DTM (14–16). After these
events, PEX5 is extracted from the DTM back into the cytosol.
This involves monoubiquitination of PEX5 at a conserved cys-
teine residue (17–20) and the ATP-dependent extraction of the
ubiquitin-PEX5 conjugate from the DTM by the mechanoen-
zymes PEX1 and PEX6, two members of the AAA family of
ATPases (14–16). Finally, ubiquitin is removed from PEX5
probably by a combination of enzymatic and nonenzymatic
processes (21, 22).
Despite all the advances made in recent years, there are still
many aspects of this protein import pathway that remain
unclear. A particularly important one regards the quaternary
structure of the PEX5-cargo protein complex formed in the
cytosol. In principle, a protein complex comprising a single
PEX5 molecule and a cargo protein should be sufficient to
ensure the correct targeting of that protein to the peroxisomal
matrix. This is probably the case for all peroxisomalmonomeric
proteins (e.g. the sterol carrier protein 2 (23)), for some oligo-
meric enzymes in which the peroxisomal targeting signals
become hidden upon oligomerization (24–27), and for natural
or artificial heterodimers in which only one of the subunits
contains peroxisomal targeting information (28–30). The situ-
ation for many other peroxisomal oligomeric proteins, how-
ever, is not that clear. Indeed, the observation that peroxisomes
have the capacity to import some already oligomerized pro-
teins, at least under conditions of high protein expression (28,
31–34), together with the fact that several peroxisomal oligo-
meric proteins may expose multiple PTS1 sequences at their
surface, could suggest that these cargo proteins are transported
to the organelle by more than one PEX5 molecule. Such a sce-
nario was in fact the central premise of one hypothetical model
proposed a few years ago aimed at describing the process of
protein translocation across the peroxisomal membrane (35).
In an effort to understand how these proteins are sorted to
the peroxisome, we started to characterize the interaction of
their monomeric and oligomeric versions with PEX5. Here, we
describe the results obtained with catalase, one of the most
abundant peroxisomal matrix proteins and probably one of the
most frequent clients of the DTM (36–38). Catalase is a heme-
containing homo-tetrameric protein in its native state (four
subunits of 60 kDa), with each subunit possessing a noncanoni-
cal PTS1 at its C terminus (KANL) (39–43). We selected cata-
lase for this initial study because there are data suggesting that
both its monomeric and tetrameric versions are substrates for
the peroxisomal protein import machinery (27, 44–49). How-
ever, whether the peroxisomal import machinery, PEX5 in par-
ticular, displays any preference for monomeric or tetrameric
catalase was unknown.
Here, we show that mammalian PEX5 bindsmonomeric cat-
alase (hereafter referred to asmCat) in amuch strongermanner
than it binds tetrameric catalase (tCat). Actually, we were
unable to detect stable PEX5-tCat complexes. Importantly,
PEX5 binding to mCat blocks its tetramerization with an IC50
in the nanomolar range. The interaction of PEX5 with mCat
was found to involve the PTS1-bindingC-terminal half of PEX5
as well as a domain(s) present in its N-terminal half. Finally, we
provide data suggesting that the PEX5-mCat interaction is dis-
rupted by the N-terminal domain of PEX14, a central compo-
nent of the DTM. The implications of these findings on the
mechanism of protein translocation across the peroxisomal
membrane are discussed.
EXPERIMENTAL PROCEDURES
Recombinant Proteins—The recombinant large isoform of
human PEX5 (50, 51), hereafter referred to as PEX5 for simplic-
ity, a protein comprising the first 324 amino acid residues of
PEX5 (C1PEX5), a protein containing amino acid residues
315–639 of PEX5 (TPRs), PEX5 containing themissensemuta-
tion N526K (PEX5N526K), a protein comprising the first 80
amino acid residues of human PEX14 (NDPEX14), and full-
length PEX19 (PEX19) were obtained as described previously
(18, 52–55). The following truncated versions of human PEX5
were also produced: PEX5N110 (amino acid residues 111–
639 of PEX5), PEX5N147 (amino acid residues 148–639 of
PEX5), PEX5N196 (amino acid residues 197–639 of PEX5),
PEX5N267 (amino acid residues 268–639 of PEX5), and
PEX5N290 (amino acid residues 291–639 of PEX5). The
cDNAs encoding these proteins were obtained by PCR using
the primers listed in supplemental Table 1 and the pQE30-
PEX5 construct as template. The amplified DNA fragments
were then digested with NdeI and SalI and cloned into the
NdeI/SalI digested pET-28c vector (Novagene). The
QuikChange site-directedmutagenesis kit (Stratagene) was
used to replace tryptophan and phenylalanine/tyrosine resi-
dues in diaromatic motifs of PEX5 by alanines (see primers in
supplemental Table 1). The three proteins obtained in this
way are as follows: PEX5N267-M7 and PEX5-M7, proteins
with amutated 7th diaromaticmotif, and PEX5-M6,7, a protein
possessing both the 6th and 7th diaromatic mutated. All plas-
mids were sequence-verified.
The cDNAencodingmouse PEX5was amplified froma com-
mercially available clone (clone MMM1013-7510385, Open
Biosystems) using the primers listed in supplemental Table 1,
digested with NdeI and SalI, and cloned into the NdeI/SalI
digested pET-28c vector. Purification of all PEX5 proteins was
done as described previously (54).
Synthesis of Radiolabeled Proteins—The cDNA encoding
full-length human catalase (clone IMAGE ID 5551309, Open
Biosystems) was amplified by PCR using the primers listed in
supplemental Table 1. This DNA was digested with XbaI and
KpnI and cloned into the XbaI/KpnI-digested pGEM-4 vector
(Promega), originating pGEM-4-Cat. This plasmid was used as
template to produce two other plasmids, one encoding a cata-
lase lacking its four last C-terminal amino acid residues
(CatKANL) and the other encoding a catalase in which these
four residues were replaced by ED (CatED). These plasmids
were obtained using the QuikChange site-directed mutagen-
esis kit (Stratagene) and the primer pairs described in supple-
mental Table 1. 35S-Labeled proteins were synthesized using
the TNT T7QuickCoupled transcription/translation kit (Pro-
mega) in the presence of [35S] methionine (specific activity
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1000 Ci/mmol; PerkinElmer Life Sciences) following the
standard conditions of the manufacturer. Unless otherwise
indicated, protein synthesis was allowed to proceed for 55 min
and was then blocked with 0.5 mM of cycloheximide (final con-
centration). Chase incubations were done at 30 °C for the spec-
ified periods of time. Chase reactions performed in the pres-
ence of recombinant proteins typically contained 6 l of the
translation mixture in a final volume of 10 l.
Native PAGE—Proteins were incubated in 10 l of 50 mM
Tris-HCl, pH 8.0, 2 mM DTT for 5 min at room temperature.
After addition of 1 l of 0.17% (w/v) bromphenol blue, 50%
(w/v) sucrose, the samples were loaded into Tris nondenatur-
ating discontinuous 8% polyacrylamide gels (56). The gels were
run at 250 V at 4 °C for 1 h (unless indicated otherwise), blotted
onto nitrocellulose membranes, stained with Ponceau S, and
exposed to an x-ray film.
Size-exclusion Chromatography—35S-Labeled proteins (50
l of in vitro transcription/translation reactions) or mixtures
containing recombinant proteins and 35S-labeled proteinswere
diluted to 250l with 50mMTris-HCl, pH 7.5, 150mMNaCl, 1
mM EDTA-NaOH, 1 mM DTT and injected into a Superose 12
10/300 GL column (GE Healthcare; loop volume 200 l) run-
ning with the same buffer at 0.5 ml/min. The column was cali-
brated with the following globular proteins: ferritin (440 kDa),
bovine serum albumin (66 kDa), and soybean trypsin inhibitor
(21.5 kDa). Fractions of 500 l were collected and subjected to
trichloroacetic acid precipitation, and one-third of each sample
was analyzed by SDS-PAGE. The gels were blotted onto nitro-
cellulose membranes, stained with Ponceau S, and exposed to
an x-ray film. Soluble mouse liver peroxisomal matrix proteins
were obtained by sonicating purified peroxisomes (prepared as
in Ref. 57) in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM
EDTA-NaOH, 1mMDTT, and 1:500 (v/v)mammalian protease
inhibitor mixture (Sigma) and centrifuging for 30 min at
100,000  g. Two hundred micrograms of soluble proteins,
supplemented or not with 300g of recombinantmouse PEX5,
were injected into the size-exclusion column, as above. Ali-
quots of 25l from each fraction were analyzed by SDS-PAGE/
Western blotting with antibodies directed to catalase (catalog
number RDI-CATALASEabr; Research Diagnostics, Inc) and
L-bifunctional protein (58).
Miscellaneous—The concentration of PEX5 in rat liver cyto-
sol (0.75 M) was calculated from the following data: total
amount of PEX5 in liver, 4 ng/g of total peroxisomal protein;
percentage of PEX5 in cytosol, 85% (59); peroxisomes, 2.5%
(w/w) of total liver protein; protein content of liver, 260 mg/g
(60); 1 g of liver corresponds to 0.94ml ofwhich 44.4% is cytosol
(61).
Theweighted averagemolecularmass ofmonomeric rat liver
peroxisomal proteins was estimated from the densitometric
analysis of a Coomassie-stained SDS gel loaded with a highly
pure peroxisomal preparation (57). Peak areas were divided by
the corresponding apparentmolecularmasses and expressed as
percentage of total moles. The weighted average of these values
is 49 kDa. For newly synthesized peroxisomal proteins, this
value may be slightly underestimated because protein matura-
tion processes that occur in the matrix of the organelle (e.g. the
cleavage of the 75-kDa acyl-CoA oxidase into the 53- and
22-kDa subunits (62)) were not taken into account. Mole per-
centage for catalase (13 mol %) was calculated considering the
mass percentage of the protein in rat liver peroxisomes, 15%
(63), the weighted average molecular mass of rat liver peroxi-
somal proteins (49 kDa), the theoretical molecular mass of cat-
alase (60 kDa), and the mass percentage of matrix proteins in
total rat liver peroxisomes, 92% (57).
The amount of total peroxisomal matrix proteins in nano-
moles/g of rat liver was calculated from the above referred data.
A value of 122 nmol/g of liver was obtained. Because “all the
major protein components of the peroxisome have the same
rate of turnover” (half-life of 1.3–1.5 days (37, 38)), one can
estimate the rate of total peroxisomal matrix protein synthesis
(k) as 30 pmol/min/g of liver. The rate of synthesis for a partic-
ular protein is k times its mole fraction in the peroxisomal
matrix. For catalase (0.13 mol fraction), this corresponds to 3.9
pmol/min/g of liver, a value similar to the one reported previ-
ously (3.87 pmol/min/g of liver (63)). The steady-state concen-
tration of newly synthesized peroxisomalmatrix proteins in the
cytosol ([P]cyt) can be estimated by the following expression:
[P]cyt k 1.443 t1⁄2, where [P]cyt is in pmol/g of liver; k is the
rate of total peroxisomal matrix protein synthesis in pmol/
min/g of liver, and t1⁄2 is the cytosolic half-life of the protein in
min (47). According to Lazarow and co-workers (46, 64), sev-
eral peroxisomal proteins display cytosolic half-lives of about 7
min (see Fig. 5 in Ref. 64). Two outliers were noted by those
authors as follows: onewas catalase, a protein presenting a cyto-
solic half-life of 14 min; the other was urate oxidase, a protein
that after 4 min of chase was already completely found in per-
oxisomes, an observation suggesting that its cytosolic half-life is
2 min or less. We assume that all peroxisomal matrix proteins
present a similar kinetic behavior, i.e. that on average their cyto-
solic half-lives are 7–8 min. The total concentration of newly
synthesized peroxisomal proteins in the cytosol is thus 0.73–
0.83 M, with mCat contributing with 0.19 M.
RESULTS
The rabbit reticulocyte lysate-based in vitro transcription/
translation system has been one of the most powerful tools for
the characterization of the molecular mechanisms underlying
protein sorting pathways. We reasoned that this system might
also be of use to study the first step of the catalase peroxisomal
import pathway, namely when and how catalase interacts with
cytosolic PEX5.
Fig. 1A shows a native-PAGE analysis of a standard in vitro
transcription/translation reaction programmed with a plasmid
encoding human catalase (lane 1). Three populations of 35S-
labeled catalase are clearly seen in these gels. Notably, when
catalase is synthesized in the presence of 1MhumanPEX5, the
two slower migrating bands are no longer detected (Fig. 1A,
lane 2). Apparently, some event(s) occurring in this system are
blocked by PEX5.
To understand the nature of the three catalase populations
detected in these experiments and thus the inhibitory effect of
PEX5, we first performed a pulse-chase analysis. In the experi-
ment shown in Fig. 1B, catalase was synthesized for 55 min;
cycloheximide was added to stop further synthesis, and the
reaction was then chased for 4 h. The autoradiograph reveals
PEX5-Catalase Interaction
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that the faster migrating species (mCat; see below) is the main
product after 55 min of synthesis. Its amount decreases during
the chase period, with the concomitant increase of the slower
migrating population (tCat). The protein band migrating
between mCat and tCat (asterisk in Fig. 1B) remains fairly con-
stant during the time course of these experiments. Its gelmigra-
tion and kinetic behavior suggest that this population might be
an oligomerization intermediate (probably a dimer), although
further data are necessary to confirm this hypothesis.
Sedimentation analysis (data not shown) and size-exclusion
chromatography (SEC; see below) of catalase before or after a
4-h chase incubation revealed that the faster migrating protein
band corresponds to species displaying the hydrodynamic
properties of a 60-kDa globular protein, whereas the protein in
the slower migrating band behaves as a 200–250-kDa protein.
Thus, the faster migrating band represents monomeric cata-
lase, whereas the slower migrating band could be either the
tetrameric enzyme or a protein complex containing catalase
and some protein(s) from the in vitro protein synthesis system
(e.g. a chaperone). To discriminate between these two possibil-
ities, we adapted the strategy originally developed by Scandalios
(65) to show that catalase is a tetrameric enzyme. For this pur-
pose, we produced an acidic mutant version of catalase
(CatED), which migrates faster than the normal enzyme in
these gels, and we asked whether this protein is able to form
heterotetramers with normal catalase upon a chase incubation
of 4 h. If this is the case, then three heterotetramers containing
1, 2, or 3molecules of the normal protein should be detected by
native-PAGE; all these heterotetramers shouldmigrate in these
gels between the homotetramers of the parental molecules. If
the slower migrating band corresponds to a complex contain-
ing catalase and some other protein(s), then the band pattern of
the protein mixture should just correspond to the sum of the
patterns obtained with each of the two catalase versions indi-
vidually. The results presented in Fig. 1C indicate that the first
possibility is the correct one.
We next asked whether PEX5 can bind mCat and tCat.
Because of the fact that the PEX5-catalase interaction is not
preserved upon native-PAGE (see below), we used SEC, a tech-
nique in which proteins can be separated in a more physiolog-
ical buffer. Translation reactions containing mCat (55 min of
synthesis) and a mixture of mCat and tCat (55 min of synthesis
plus 4 h of chase) were first subjected to SEC to purifymCat and
tCat, respectively. Each of these proteins was then incubated
with PEX5 or buffer alone and subjected to a second SEC. The
results obtained with mCat are presented in Fig. 2A. In the
absence of PEX5, the radiolabeled protein present in fraction 24
of the first SEC (Fig. 2A, panel 1) still elutes as a monomeric
protein in the second SEC (panel 2), indicating that no
tetramerization of mCat occurs during this procedure. In con-
trast, in the presence of PEX5, the elution volume of mCat is
reduced, and the radiolabeled protein elutes now together with
recombinant PEX5 (Fig. 2A, panels 3 and 4). Thus, PEX5 inter-
acts with mCat. A different result was obtained for tCat. As
shown in Fig. 2B, the elution profiles of tCat in the presence or
absence of PEX5 are almost identical (Fig. 2B, panels 2 and 3)
suggesting that these two proteins may interact only weakly.
(Note that amajor fraction of tCat co-elutes with PEX5 (Fig. 2B,
compare panels 2 and 4) implying that, contrary to the situation
with mCat, the two proteins are kept under near-equilibrium
conditions during chromatography. This should facilitate the
detection of PEX5-tCat complexes.) We also did not find evi-
dence for the existence of a PEX5-tCat protein complex when
mouse liver peroxisomal matrix proteins preincubated with
either recombinantmouse PEX5 or buffer alonewere subjected
to SEC. Indeed, the elution volume of mouse catalase remains
basically the same regardless of the presence of PEX5 (Fig. 2C,
panels 1 and 2). This behavior contrasts to the one displayed by
the L-bifunctional protein, a monomeric 78-kDa protein in its
native state (58), which elutes much earlier in the presence of
PEX5 (Fig. 2C, panels 4) than in its absence (panel 3). We still
tried to detect a PEX5-tCat interaction by subjecting 35S-la-
beled tCat or mouse liver native catalase to ultracentrifugation
FIGURE1. 35S-Labeledcatalase tetramerizes invitro.A,humancatalasewas
synthesized in vitro in a rabbit reticulocyte lysate for 90 min at 30 °C in the
absence or presence of 1 M human PEX5, as indicated, and analyzed by
native-PAGE/autoradiography. B, 35S-labeled catalase was synthesized for 55
min. After adding cycloheximide, an aliquotwas removedand frozen in liquid
N2 (lane 55). The remainder of the reaction was then incubated at 30 °C, and
aliquots were removed and frozen at the indicated time points. The samples
were subjected to native-PAGE/autoradiography. The protein bands labeled
with mCat and tCat correspond to the monomeric and tetrameric forms of
catalase; the band labeled with an asterisk probably represents dimeric cata-
lase (see text for details).C, catalase and amutant version of it possessing two
acidic amino acid residues at the C terminus (CatED)were synthesized in vitro
for 55 min and supplemented with cycloheximide (lanes 1 and 2, respec-
tively). Aliquots of each reactionwere then combinedand incubated for 4hat
30 °C (lane4) or incubated individuallyunder the sameconditions (lanes 3and
5 for catalase and CatED, respectively), and subjected to native PAGE/autora-
diography. Note that this gel was run for 2.5 h to improve separation of
tetramers. Longer electrophoretic runs also result in more diffuse bands. The
dots in lane 4 indicate the three expected heterotetramers. mCatED and
tCatED indicate the monomeric and tetrameric forms of CatED, respectively.
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through a solution containing 1 M PEX5. Again, no evidence
for a PEX5-tCat protein complex was obtained.5 Thus, if tCat
interacts with PEX5, the Kd value of the interaction is larger
than 1 M. We note that interactions between PEX5 and
recombinant catalase have been described before, but no quan-
titative binding data were reported (45, 66). Regardless of these
uncertainties, it is clear from our results that PEX5 binds stron-
ger to mCat than to tCat. Considering that tCat, unlike mCat,
contains four PTS1 sequences, a property that should increase
the stability of a putative complex with PEX5 because of an
avidity effect, this is an unexpected finding. Apparently, some
domain of the catalase polypeptide chain involved in the inter-
action with PEX5 is no longer accessible when the protein
tetramerizes.
The results presented above indicate that PEX5 binds mCat
blocking its tetramerization. We explored this phenomenon to
further characterize the PEX5-catalase interaction. In the
experiments described below, in vitro synthesized catalase was
chased for 4 h in the presence of several recombinant proteins
and analyzed by native-PAGE. As shown in Fig. 3A, PEX5, at 1
M in the chase incubation, completely blocked catalase
tetramerization, as expected. The inhibitory effect of PEX5 is
quite strong displaying an IC50 of about 100 nM (Fig. 3B). No
such effect was observed with PEX5(N526K), a mutant PEX5
molecule possessing a single missense mutation in the PTS1-
binding domain that abolishes its activity (Fig. 3A) (67, 68). A
similar result was obtained when a mutant version of catalase
lacking the PTS1 (CatKANL)was used in this assay; tetramer-
ization of this species was no longer sensitive to the inhibitory
action of PEX5 (Fig. 3C, compare lane 3 with 6). Thus, inhibi-
tion of catalase tetramerization by PEX5 requires the interac-
tion of catalase PTS1 sequencewith theC-terminal PTS1-bind-
ing domain of PEX5. Interestingly, however, this domain of
PEX5 alone (referred to as TPRs) does not display this capacity
when tested in this assay at a 1 M concentration (Fig. 3D, lane
5), and the same is true for a recombinant protein comprising
the N-terminal half of PEX5 (C1PEX5; Fig. 3D, lane 4). Like-
wise, a mixture of these two domains of PEX5, both at 1 M,
does not interfere with catalase tetramerization (Fig. 3D, lane
6), suggesting that these two domains of PEX5 have to reside in
the samemolecule (i.e. they have to be in a cis configuration) to
inhibit catalase tetramerization at this concentration.
A plausible explanation for this finding is that domains pres-
ent in both halves of PEX5 contribute to the interaction with
mCat. We tested this hypothesis by performing additional
tetramerization assays but this time using 200-fold larger con-
centrations of TPRs and C1PEX5 in the chase incubations.
PEX19, a protein involved in a different aspect of peroxisomal
biogenesis (reviewed in Ref. 69), was used as a negative control.
5 M. O. Freitas and J. E. Azevedo, unpublished results.
FIGURE 2. PEX5 bindsmonomeric catalase. A, 35S-labeled catalase was syn-
thesized in vitro for 55minandsubjected toSEC. RadiolabeledmCateluting in
fraction24of this chromatography (panel 1, boxed lane)was thensubjected to
a second SEC either alone (panel 2) or after receiving 1M recombinant PEX5
(panels 3 and 4). Fractions were collected and subjected to SDS-PAGE/West-
ern blotting. Autoradiographs (panels 1–3) and the Ponceau S-stained mem-
brane showing PEX5 (panel 4) are presented. No recombinant PEX5 or 35S-
labeledcatalaseweredetected in thevoidvolumeof this column (fractions14
and 15; not shown). The asteriskmarks bovine serum albumin added to chro-
matography fractions before precipitation to control protein recoveries.
B, 35S-labeled catalase, synthesized in vitro for 55min and incubated for 4 h at
30 °C in the presence of cycloheximide, was subjected to SEC. Radiolabeled
tCat eluting in fraction20 (panel 1, boxed lane)was then subjected to a second
SEC either alone (panel 2) or after receiving 1M recombinant PEX5 (panels 3
and 4). Fractions were processed as described above. Autoradiographs (pan-
els 1–3) and the Ponceau S-stained membrane (panel 4) are presented.
C, soluble proteins frommouse liver peroxisomeswere incubated either with
recombinant PEX5 or buffer alone and subjected to SEC. Fractions were
subjected to SDS-PAGE/Western blotting using antibodies directed to cata-
lase (PerCat) or L-bifunctional protein. Immunoblots (panels 1–4) and a Pon-
ceau S-stained membrane showing PEX5 (panel 5) are presented. Note that
PEX5, a monomeric 70-kDa protein in solution, displays an abnormal behav-
ior upon SEC because a major fraction of its polypeptide chain is natively
unfolded (52).
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These experiments revealed thatC1PEX5 displays a weak but
reproducible (n  5) inhibitory effect on catalase tetrameriza-
tion (Fig. 3E). A complete inhibition of catalase tetramerization
is observed in the presence of 200 M TPRs (Fig. 3E). Interest-
ingly, there is an increase in the intensity of the band migrating
betweenmCat and tCat in the sample chased in the presence of
TPRs. This observation could suggest that TPRs does not
inhibit catalase dimerization, although further data will be nec-
essary to corroborate this interpretation. In summary, these
data suggest the PEX5-mCat interaction involves domains
present in both halves of PEX5.
After binding a newly synthesized peroxisomal protein in the
cytosol, PEX5 docks at the DTM and promotes the transloca-
tion of its cargo across the organelle membrane. At the end of
this process, DTM-embedded PEX5 has to release its cargo into
the organelle matrix. Previous work in yeast suggested that
PEX8, an intraperoxisomal component of the DTM, performs
this task (70). However, mammals and many other organisms
lack a PEX8 ortholog (71), and so the triggering mechanism for
this event remains unknown. If we assume that a similar mech-
anism also operates in mammals, i.e. a DTM component inter-
acts with PEX5 triggering the release of cargo into the organelle
matrix, as the presently available data suggest (see Introduc-
tion), then a good candidate to perform this task is PEX14.
PEX14 is an intrinsic membrane protein possessing a single
putative transmembrane domain. Its C-terminal two-thirds are
exposed into the cytosol, whereas its N-terminal domain is
either embedded in the peroxisomal membrane or even
exposed into the matrix of the organelle (72, 73). The interac-
tion of PEX5 with the N-terminal domain of PEX14 is well
documented but still poorly understood in mechanistic terms.
Indeed, it is known that this domain of PEX14 (hereafter
referred to as NDPEX14) interacts strongly with seven diaro-
matic motifs located at the N-terminal half of PEX5, some of
which are indispensable for the function of PEX5 (66, 74, 75),
but the reason for this complex mode of binding is unknown.
Thus, we asked whether NDPEX14 affects the PEX5-mCat
interaction. For this purpose, we purified 35S-labeled mCat by
SEC and incubated the radiolabeled protein with 1 M recom-
binant PEX5 to generate the PEX5-mCat protein complex. This
complex was then subjected to SEC either alone or after receiv-
ing 15 M NDPEX14. As shown in Fig. 4, in the presence of
NDPEX14, the elution volume of PEX5 is decreased (compare
panel 3with 5) indicating that a PEX5-NDPEX14 protein com-
plex was formed. Importantly, under these conditions the vast
majority of mCat elutes now as a monomeric protein (Fig. 4,
compare panel 2 with 4). Thus, binding of NDPEX14 to PEX5
disrupts the PEX5-mCat interaction.
FIGURE 3. PEX5 inhibits catalase tetramerization. A, 35S-labeled catalase was synthesized in vitro for 55 min (lane 55) and chased for 4 h in the absence
(lane) or presence of 1M of the indicated recombinant proteins. B, same as in A, but using the indicated concentrations of PEX5. C, catalase (lanes 1–3) and
a truncated version of it lacking the PTS1 signal (catalaseKANL; lanes 4–6) were synthesized for 55min and chased in the absence (lanes 2 and 5) or presence
of 1 M PEX5 (lanes 3 and 6). D, 35S-labeled catalase was synthesized in vitro for 55 min (lane 1) and chased in the absence (lane 2) or presence of 1 M of the
indicated recombinant proteins (lanes 3–6).C1PEX5 and TPRs, recombinant proteins comprising the N- and C-terminal half of PEX5, respectively. E, same as
in A, but using 200M of the indicated recombinant proteins. Samples were analyzed by native-PAGE/autoradiography. Note that the gel shown in Cwas run
for 2.5 h.mCat and tCat, monomeric and tetrameric versions of catalase, respectively;mCat and tCat, monomeric and tetrameric forms of catalaseKANL,
respectively.
PEX5-Catalase Interaction
40514 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286•NUMBER 47•NOVEMBER 25, 2011
 by Jorge Azevedo, on Decem
ber 6, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
To better understand how NDPEX14 affects the mCat bind-
ing activity of PEX5, we produced several truncated forms of
recombinant PEX5 (see Fig. 5A), and after evaluating their
monodispersity and capacity to interact with NDPEX14 by
native-PAGE (see supplemental Fig. S1), we tested them in the
in vitro catalase tetramerization assay in the absence or pres-
ence ofNDPEX14.The aimof these experimentswas to identify
the smallest PEX5 truncated molecule that still retains the
capacity to bind mCat at low concentrations (i.e. 1 M), as
assessed by its capacity to inhibit tetramerization of the
enzyme, and to determine whether the PEX14-binding diaro-
matic motif(s) present in this molecule is(are) involved in the
disruption of the PEX5-mCat interaction. As shown in Fig. 5B
(upper panel), PEX5N110, PEX5N147 and PEX5N196,
proteins lacking the first 110, 147 or 196 amino acid residues of
PEX5, respectively, are as potent as full-length PEX5 in this
assay. As expected from the data presented in Fig. 4, neither
full-length PEX5nor any of these truncated proteins displays an
inhibitory effect on catalase tetramerization in the presence of
NDPEX14 (Fig. 5B, lower panel). PEX5N267, a protein con-
taining only the 7th diaromatic motif of PEX5, still inhibits
catalase tetramerization, although in a less potent manner.
Again, this inhibitory effect is abolished in the presence of
NDPEX14 (Fig. 5B, lower panel). In contrast, PEX5N290 dis-
plays no inhibitory activity (Fig. 5B, upper panel). Taken
together, these results suggest that the region between amino
acid residues 197 and 290 of PEX5 is involved in the mCat-
PEX5 interaction and that binding of NDPEX14 to the single
diaromatic motif present in PEX5N267 is sufficient to disrupt
that interaction.
Unexpectedly, substitution of the tryptophan and tyrosine
residues in the diaromatic motif of PEX5N267 by alanines,
mutations that affect its PEX14 binding activity (66, 74), results
in a protein, PEX5N267-M7, that no longer inhibits catalase
tetramerization (Fig. 5C), suggesting that these two aromatic
residues are structurally important. Interestingly, when the
same mutation was introduced in full-length PEX5, the result-
ing protein, PEX5-M7, was found to be as potent as the normal
protein in inhibiting catalase tetramerization as well as in its
response to NDPEX14 (Fig. 5D). This observation suggests, on
one hand, that other regions of PEX5 compensate for the alter-
ations associated with the mutation at 7th diaromatic motif,
and, on the other hand, that at least one of the remaining six
diaromatic motifs present in PEX5-M7 is involved in the
NDPEX14-induced disruption of the mCat-PEX5 interaction.
Data suggesting that the 6th diaromatic motif of PEX5 plays a
major role in the NDPEX14-induced disruption of the mCat-
PEX5 interaction were obtained when recombinant PEX5-
M6,7, a PEX5 protein mutated at both the 6th and 7th diaro-
matic motifs, was tested in the catalase tetramerization assay.
As shown in Fig. 5D, PEX5-M6,7 displays an inhibitory activity
in this assay, although in a less potent manner than PEX5. This
finding again suggests that the structure/function of this region
of PEX5 required for the interaction with mCat is not fully
preserved upon mutation of the diaromatic motifs. Impor-
tantly, the inhibitory activity of PEX5-M6,7 is no longer signif-
icantly neutralized by NDPEX14. These results suggest that
binding of NDPEX14 to the 6th diaromatic motif of PEX5 and
probably also to the 7th motif (as inferred from the
PEX5N267 data) disrupts the mCat-PEX5 interaction.
DISCUSSION
The proposed mechanism for the catalase assembly pathway
consists of three steps as follows: 1) apo-monomers heme3
holomonomers; 2) holomonomers 3 holodimers; and 3)
holodimers3homotetramers (reviewed inRef. 76). The step at
which PEX5 binds and transports catalase to the peroxisome,
however, has remained a controversial issue. In this work, we
used an in vitro system to characterize the PEX5-catalase inter-
action. Our results suggest that in the presence of PEX5 step 3
no longer occurs, but whether the inhibitory effect of PEX5 is
exerted at step 1 and/or 2 remains unknown. Nevertheless, it is
interesting to note that themCat species is a soluble andmono-
disperse protein suggesting that it already possesses a near-
native conformation.
Unexpectedly, a qualitative assessment of the binding affini-
ties of mCat and tCat for PEX5 revealed that PEX5 has a bias
toward binding the former, suggesting that some domain of the
catalase polypeptide chain is no longer available to interactwith
PEX5 when the protein tetramerizes. If we exclude catalase
FIGURE 4. N-terminal domain of PEX14 disrupts the mCat-PEX5 interac-
tion. 35S-Labeled mCat was purified by SEC (panel 1, fraction 24), supple-
mentedwith 1M recombinant PEX5 and incubated for 30min at room tem-
perature to generate the PEX5-mCat protein complex. Half of this samplewas
analyzeddirectly by SEC (panels 2 and 3). Theother half received recombinant
NDPEX14 (15 M) 30 min before chromatography (panels 4 and 5). Fractions
were subjected to SDS-PAGE and blotted onto a nitrocellulose membrane.
Autoradiographs (panels 1, 2, and 4) and the Ponceau S-stained membranes
(panels 3 and 5) are presented. Hb, hemoglobin from the reticulocyte lysate
that co-purified with mCat in the first SEC.
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PTS1 from this reasoning, as the crystal structures of catalase
might suggest (39, 40, 42), it is reasonable to assume that
another domain of the mCat protein is involved in this phe-
nomenon. Data supporting this possibility were obtained when
we focused our attention on PEX5. Indeed, we found that the
PTS1-binding domain of PEX5 is required for the mCat-PEX5
interaction, as expected, but evidence for the participation of an
N-terminal domain of PEX5 in this interaction was also
obtained. Each of these two PEX5 domains alone (i.e. in trans)
can bind mCat inhibiting its tetramerization, but this effect is
dramatically increased when these domains reside in the same
molecule. Thus, they most likely bind mCat simultaneously.
The conclusion that the catalase-binding interface in PEX5
encompasses more than its PTS1-binding domain is probably
also valid for other organisms. Indeed, as shown previously,
yeast catalase possesses peroxisomal targeting information in
two different regions of its polypeptide chain, one at the C ter-
minus (the PTS1 sequence) and the other located in its N-ter-
minal third (77), an observation that would be compatible with
the existence of two different catalase-binding domains in yeast
PEX5. Likewise, the observation that pumpkin catalase inter-
acts with the N-terminal half of PEX5 in the yeast two-hybrid
system (78), together with data on cottonseed catalase showing
that its last four residues (which are conserved in pumpkin cat-
alase) are sufficient to target a reporter protein to the peroxi-
some (79), could suggest that plant PEX5 possesses more than
one catalase-interacting domain.
As already mentioned, binding of PEX5 to mCat inhibits its
tetramerization in a potent manner. This previously unknown
capacity of PEX5 evokes the properties of a family of bacterial
chaperones functioning in type III secretion systems. These
chaperones, some of which also contain tetratricopeptide
repeats, bind proteins to be secreted in the cytoplasm prevent-
ing premature or incorrect interactions and participate in the
secretion step itself (Ref. 80 and reviewed in Ref. 81). Although
additional data will be necessary to reinforce the functional
similarities between PEX5 and these chaperones, it is interest-
ing to note that we have recently observed the same phenome-
non when studying another oligomeric peroxisomal protein.5
Regardless of the mechanistic reasons behind the inhibitory
activity of PEX5 on peroxisomal protein oligomerization, it is
evident that such a property may be biologically relevant only if
the amount of cytosolic PEX5 in a cell is sufficient to sequester
mCat and all the other newly synthesized peroxisomal proteins
that are en route to the organelle. The data available for rat liver
suggest that thismaywell be the case. Indeed, we estimated that
the cytosolic concentration of PEX5 is 0.75 M, whereas the
concentration of newly synthesized peroxisomal proteins is
0.73–0.83 M, with mCat occupying a major fraction of this
pool (0.19 M; see under “Experimental Procedures” for
details). Thus, even if we assume that newly synthesized perox-
isomal proteins become available to bind PEX5 immediately
after their synthesis (i.e. their folding process is not incompat-
ible with PEX5 binding), we still reach the conclusion that there
is a sufficient amount of PEX5 to bind a significant fraction of
mCat.
The results presented here thus corroborate and extend the
pioneering observations of Lazarow and de Duve (46, 47) sug-
gesting that rat liver catalase arrives at the peroxisome still in its
monomeric state. However, they also seem to collide with the
idea that catalase is imported into the organelle only after
tetramerization (49). This is not completely so. Indeed, as dis-
cussed above, the crucial factor determining whether or not
catalase tetramerizes before import may well be the amount of
PEX5 present in the cytosol. If a cell contains a stoichiometric
excess of PEX5 over newly synthesized peroxisomal proteins,
FIGURE 5. PEX5 diaromatic motifs involved in the NDPEX14-induced disruption of themCat-PEX5 interaction. A, schematic representation of recom-
binant PEX5 proteins. The diaromatic motifs in the N-terminal half of PEX5 are numbered 1–7. Replacement of tryptophan and phenylalanine/tyrosine
residues by alanines in these motifs is indicated by X. B–D, 35S-labeled catalase was synthesized in vitro for 55 min (lane 55) and chased for 4 h in the
absence (lane) or presence of 1 M of the indicated recombinant PEX5 proteins alone or together with NDPEX14 (30 M). Samples were analyzed by
native-PAGE/autoradiography.
FIGURE 6. Role of PEX14 in the release of cargo proteins into the peroxi-
somalmatrix. A newly synthesized cargo protein (CP) is recognized by PEX5
in the cytosol. This protein complex then docks at and becomes inserted into
the peroxisomal DTM of which only PEX14 is shown for simplicity. The DTM
component(s) providing thedocking site for the PEX5-cargoprotein complex
have not been unambiguously identified yet. As discussed elsewhere, two
strong candidates for this role are PEX13 (86) and PEX14 itself (87, 88). Note
that PEX13 may also participate in the cargo-release step (66). The multiple
interactions of PEX5 with the N-terminal domain of the several PEX14 mole-
cules present in the DTM ultimately trigger the release of the cargo into the
peroxisomal matrix.
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then it is likely that catalase remains monomeric and is
imported as such; if not, a fraction of it will tetramerize before
import. Although speculative, this possibility would explain
why different results are obtained in different experimental sys-
tems (see Ref. 49 and references therein).
PEX14, a central component of the DTM, was regarded for
many years as a protein involved solely in the docking of the
receptor at the peroxisomal membrane (82). However, several
observations have challenged this concept, and it is now clear
that this protein also participates in the translocation of cargoes
across the peroxisomalmembrane (83, 84). The finding that the
N-terminal domain of human PEX14 disrupts the PEX5-mCat
interaction together with data reported earlier for Leishmania
donovani PEX5 showing that its affinity for a PTS1 protein is
decreased in the presence of PEX14 (85) suggest still another
function for this membrane protein, a role in the release of
cargoes from DTM-embedded PEX5 into the peroxisomal
matrix.
Interestingly, from the seven diaromatic motifs present in
human PEX5, only one or two play a major role in the
NDPEX14-induced disruption of the mCat-PEX5 interaction.
This finding together with previous data showing that diaro-
matic motifs 2–4 of PEX5 are required for catalase import in
vivo (66) suggests that the multiple interactions that are prob-
ably established between the N-terminal domain of peroxi-
somal PEX14 and the diaromatic motifs present in PEX5 occur
in a sequential manner and may serve two different purposes.
According to this hypothetical model (see Fig. 6), the first set of
interactions may contribute to the docking/insertion of the
PEX5-cargo protein complex into the DTM; subsequently,
binding of additional PEX14molecules to the 6th (and probably
7th) diaromatic motif(s) of PEX5 would trigger the release of
the cargo protein into the peroxisomal matrix.
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